

Publikationen aus der Psychiatrischen Klinik 2019

Anzahl Publikationen: 289

IF-relevante Publikationen: 213

Summe IF: 1227.365

1. **Adorjan K, Falkai P**
Premature mortality, causes of death, and mental disorders.
Lancet. 2019 Nov 16;394(10211):1784-1786. doi: 10.1016/S0140-6736(19)32521-8.
IF 60.392
2. **Adorjan K, Falkai P, Pogarell O**
[Catatonia in clinical reality: underdiagnosed and forgotten].
MMW Fortschr Med. 2019 Dec;161(Suppl 7):7-11. doi: 10.1007/s15006-019-1173-5.
IF -
3. **Adorjan K, Karch S, Martin G, Plörer D, Winter C, Hantschk I, Koller G, Erbas B, Pogarell O**
[Adult attention deficit hyperactivity disorder (ADHD) with comorbid addictive disorder. Therapeutic challenges using the example of a survey of clinical practice].
MMW Fortschr Med. 2019 Jul;161(Suppl 5):7-12. doi: 10.1007/s15006-019-0740-0.
IF -
4. **Adorjan K, Papiol S**
Genetic risk of psychosis in relation to cannabis use: findings from polygenic risk score approaches.
J Psychiatry Brain Sci 2019; 4: e190018. IF -
5. **Alexopoulos P, Thierjung N, Economou P, Werle L, Buhl F, Kagerbauer S, Papanastasiou AD, Grimmer T, Gourzis P, Berthele A, Hemmer B, Kübler H, Martin J, Politis A, Perneczky R**
Plasma Levels of Soluble A β PP β as a Biomarker for Alzheimer's Disease with Dementia.
J Alzheimers Dis. 2019;69(1):83-90. doi: 10.3233/JAD-181088. IF 3.909
6. **Ambrée O, Ruland C, Zwanzger P, Klotz L, Baune BT, Arolt V, Scheu S, Alferink J**
Social Defeat Modulates T Helper Cell Percentages in Stress Susceptible and Resilient Mice.
Int J Mol Sci. 2019 Jul 17;20(14). pii: E3512. doi: 10.3390/ijms20143512. IF 4.556
7. **Anderson-Schmidt H, Gade K, Malzahn D, Papiol S, Budde M, Heilbronner U, Reich-Erkelenz D, Adorjan K, Kalman JL, Senner F, Comes AL, Flatau L, Gryaznova A, Hake M, Reitt M, Schmauß M, Juckel G, Reimer J, Zimmermann J, Figge C, Reininghaus E, Anghelescu IG, Konrad C, Thiel A, von Hagen M, Koller M, Stierl S, Scherk H, Spitzer C, Folkerts H, Becker T, Dietrich DE, Andlauer TFM, Degenhardt F, Nöthen MM, Witt SH, Rietschel M, Wiltfang J, Falkai P, Schulze TG**
The influence of religious activity and polygenic schizophrenia risk on religious delusions in schizophrenia.
Schizophr Res. 2019 Aug;210:255-261. doi: 10.1016/j.schres.2018.12.025. IF 3.759

8. **Angst J, Rössler W, Ajdacic-Gross V, Angst F, Wittchen HU, Lieb R, Beesdo-Baum K, Asselmann E, Merikangas KR, Cui L, Andrade LH, Viana MC, Lamers F, Penninx BW, de Azevedo Cardoso T, Jansen K, Dias de Mattos Souza L, Azevedo da Silva R, Kapczinski F, Grobler C, Gholam-Rezaee M, Preisig M, Vandeley CL**
Differences between unipolar mania and bipolar-I disorder: Evidence from nine epidemiological studies.
Bipolar Disord. 2019 Aug;21(5):437-448. doi: 10.1111/bdi.12732. IF 5.410
9. **Arnau-Soler A, Macdonald-Dunlop E, Adams MJ, Clarke TK, MacIntyre DJ, Milburn K, Navrady L; Generation Scotland; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Hayward C, McIntosh AM, Thomson PA**
Genome-wide by environment interaction studies of depressive symptoms and psychosocial stress in UK Biobank and Generation Scotland.
Transl Psychiatry. 2019 Feb 4;9(1):14. doi: 10.1038/s41398-018-0360-y. IF 5.280
10. **Arteaga-Henríquez G, Simon MS, Burger B, Weidinger E, Wijkhuijs A, Arolt V, Birkenhager TK, Musil R, Müller N, Drexhage HA**
Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium.
Front Psychiatry. 2019 Jul 9;10:458. doi: 10.3389/fpsy.2019.00458. eCollection 2019. IF 2.849
11. **Baeken C, Brem AK, Arns M, Brunoni AR, Filipčić I, Ganho-Ávila A, Langguth B, Padberg F, Poulet E, Rachid F, Sack AT, Vanderhasselt MA, Bennabi D**
Repetitive transcranial magnetic stimulation treatment for depressive disorders: current knowledge and future directions.
Curr Opin Psychiatry. 2019 Sep;32(5):409-415. doi: 10.1097/YCO.0000000000000533. IF 4.392
12. **Bartoletti-Stella A, Corrado P, Mometto N, Baiardi S, Durrenberger PF, Arzberger T, Reynolds R, Kretzschmar H, Capellari S, Parchi P**
Analysis of RNA Expression Profiles Identifies Dysregulated Vesicle Trafficking Pathways in Creutzfeldt-Jakob Disease.
Mol Neurobiol. 2019 Jul;56(7):5009-5024. doi: 10.1007/s12035-018-1421-1. IF 4.500
13. **Barton BB, Musil R**
Posttraumatische Belastungsstörung.
Deutsche Zeitschrift für Akupunktur 2019; 62: 24-27. IF -
14. **Batra A, Düerkop M, Gertzen M, Jähne A, Mühlig S, Rüther T**
Nikotin.
In: Soyka M, Batra A, Heinz A, Moggi F, Walter M (Hrsg.)
Suchtmedizin.
Elsevier, München, 2019, S. 237-258.
15. **Batra A, Jähne A, Rüther T**
Tabakabhängigkeit (ICD-10 F 17.2).
In: Voderholzer U, Hohagen F (Hrsg.)
Therapie psychischer Erkrankungen. State of the Art.
Elsevier, Urban & Fischer, München, 2019, S. 81-92.

16. **Beller E, Keeser D, Wehn A, Malchow B, Karali T, Schmitt A, Papazova I, Papazov B, Schoeppe F, de Figueiredo GN, Ertl-Wagner B, Stoecklein S**
T1-MPRAGE and T2-FLAIR segmentation of cortical and subcortical brain regions-
an MRI evaluation study.
Neuroradiology. 2019 Feb;61(2):129-136. doi: 10.1007/s00234-018-2121-2. IF 2.238
17. **Betz LT, Brambilla P, Ilankovic A, Premkumar P, Kim MS, Raffard S, Bayard S, Hori H, Lee KU, Lee SJ, Koutsouleris N, Kambeitz J**
Deciphering reward-based decision-making in schizophrenia: A meta-analysis and
behavioral modeling of the Iowa Gambling Task.
Schizophr Res. 2019 Feb;204:7-15. doi: 10.1016/j.schres.2018.09.009. IF 3.759
18. **Beyer L, Schnabel J, Kazmierczak P, Ewers M, Schönecker S, Prix C, Meyer-Wilmes J, Unterrainer M, Catak C, Pogarell O, Perneczky R, Albert NL, Bartenstein P, Danek A, Buerger K, Levin J, Rominger A, Brendel M**
Neuronal injury biomarkers for assessment of the individual cognitive reserve in
clinically suspected Alzheimer's disease.
Neuroimage Clin. 2019;24:101949. doi: 10.1016/j.nicl.2019.101949. IF 4.350
19. **Bloch C, Vogeley K, Georgescu AL, Falter-Wagner CM**
Intrapersonal Synchrony as Constitutive of Interpersonal Synchrony and its
Relevance for Autism-Spectrum-Disorder.
Frontiers in Robotics and AI 2019; 6(73): 1-8. doi: 10.3389/frobt.2019.00073.
eCollection 2019. IF -
20. **Blumenstock S, Angelo MF, Peters F, Dorostkar MM, Ruf VC, Luckner M, Crux S, Slapakova L, Arzberger T, Claverol S, Herzog E, Herms J**
Early defects in translation elongation factor 1 α levels at excitatory synapses in α -
synucleinopathy.
Acta Neuropathol. 2019 Dec;138(6):971-986. doi: 10.1007/s00401-019-02063-3.
IF 14.251
21. **Bonham LW, Steele NZR, Karch CM, Broce I, Geier EG, Wen NL, Momeni P, Hardy J, Miller ZA, Gorno-Tempini ML, Hess CP, Lewis P, Miller BL, Seeley WW, Manzoni C, Desikan RS, Baranzini SE, Ferrari R, Yokoyama JS; International FTD-Genomics Consortium (IFGC)**
Genetic variation across RNA metabolism and cell death gene networks is implicated
in the semantic variant of primary progressive aphasia.
Sci Rep. 2019 Jul 26;9(1):10854. doi: 10.1038/s41598-019-46415-1. IF 3.998
22. **Brandl F, Avram M, Weise B, Shang J, Simões B, Bertram T, Hoffmann Ayala D, Penzel N, Gürsel DA, Bäuml J, Wohlschläger AM, Vukadinovic Z, Koutsouleris N, Leucht S, Sorg C**
Specific Substantial Dysconnectivity in Schizophrenia: A Transdiagnostic
Multimodal Meta-analysis of Resting-State Functional and Structural Magnetic
Resonance Imaging Studies.
Biol Psychiatry. 2019 Apr 1;85(7):573-583. doi: 10.1016/j.biopsych.2018.12.003.
IF 12.095
23. **Brown P, RELISH Consortium and Yaoqi Zhou**
Large-expert-curated database for benchmarking document similarity detection in
biomedical literature search.
Database 2019; 1-66. doi: 10.1093/database/baz085. IF 2.593

24. **Brugnolo A, De Carli F, Pagani M, Morbelli S, Jonsson C, Chincarini A, Frisoni GB, Galluzzi S, Perneczky R, Drzezga A, van Berckel BNM, Ossenkoppele R, Didic M, Guedj E, Arnaldi D, Massa F, Grazzini M, Pardini M, Mecocci P, Dottorini ME, Bauckneht M, Sambuceti G, Nobili F**
Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease.
J Alzheimers Dis. 2019;68(1):383-394. doi: 10.3233/JAD-181022. IF 3.909

25. **Brunelin J, Mondino M, Arns M, Baeken C, Brem AK, Filipčić I, Ganho-Avila A, Palm U, Poleszczuk A, Sauvaget A, O'Shea J, D'Urso G, Poulet E**
3rd European Conference on brain stimulation in psychiatry - From mechanism to medicine.
Encéphale. 2019 Jun;45 Suppl 2:S47-S49. doi: 10.1016/j.encep.2019.04.001. IF 0.873

26. **Brunnauer A**
Leistungsdiagnostik bei psychischen Erkrankungen.
Zeitschrift für Verkehrssicherheit 2019; 2: 102-103.

27. **Brunnauer A, Laux G**
Antidepressiva und Fahrtauglichkeit – ein Update klinischer Untersuchungen.
Gynäkologische Praxis 2019; 44: 511-519. IF -

28. **Brunoni AR, Palm U**
Transcranial Direct Current Stimulation in Psychiatry: Mood Disorders, Schizophrenia and Other Psychiatric Diseases.
In: Knotkova H, Nitsche M; Bikson M, Woods AJ (eds).
Practical Guide to Transcranial Direct Current Stimulation. Springer, 2019, pp 431-471.

29. **Brunoni AR, Sampaio-Junior B, Moffa AH, Aparício LV, Gordon P, Klein I, Rios RM, Razza LB, Loo C, Padberg F, Valiengo L**
Noninvasive brain stimulation in psychiatric disorders: a primer.
Braz J Psychiatry. 2019 Jan-Feb;41(1):70-81. doi: 10.1590/1516-4446-2017-0018. IF -

30. **Budde M, Anderson-Schmidt H, Gade K, Reich-Erkelenz D, Adorjan K, Kalman JL, Senner F, Papiol S, Andlauer TFM, Comes AL, Schulte EC, Klöhn-Saghatolislam F, Gryaznova A, Hake M, Bartholdi K, Flatau L, Reitt M, Quast S, Stegmaier S, Meyers M, Emons B, Haußleiter IS, Juckel G, Nieratschker V, Dannlowski U, Schuapp SK, Schmauß M, Zimmermann J, Reimer J, Schulz S, Wiltfang J, Reininghaus E, Anghelescu IG, Arolt V, Baune BT, Konrad C, Thiel A, Fallgatter AJ, Figge C, von Hagen M, Koller M, Lang FU, Wigand ME, Becker T, Jäger M, Dietrich DE, Stierl S, Scherk H, Spitzer C, Folkerts H, Witt SH, Degenhardt F, Forstner AJ, Rietschel M, Nöthen MM, Falkai P, Schulze TG, Heilbronner U**
A longitudinal approach to biological psychiatric research: The PsyCourse study.
Am J Med Genet B Neuropsychiatr Genet. 2019 Mar;180(2):89-102. doi: 10.1002/ajmg.b.32639. IF 3.387

31. **Budde M, Friedrichs S, Alliey-Rodriguez N, Ament S, Badner JA, Berrettini WH, Bloss CS, Byerley W, Cichon S, Comes AL, Coryell W, Craig DW, Degenhardt F, Edenberg HJ, Foroud T, Forstner AJ, Frank J, Gershon ES, Goes FS, Greenwood TA, Guo Y, Hipolito M, Hood L, Keating BJ, Koller DL, Lawson WB, Liu C, Mahon PB, McInnis MG, McMahon FJ, Meier SM, Mühleisen TW, Murray SS, Nievergelt CM, Nurnberger JI Jr, Nwulia EA, Potash JB, Quarless D, Rice J, Roach JC, Scheftner WA, Schork NJ, Shekhtman T, Shilling PD, Smith EN, Streit F, Strohmaier J, Szelinger S, Treutlein J, Witt SH, Zandi PP, Zhang P, Zöllner S, Bickeböller H, Falkai PG, Kelsoe JR, Nöthen MM, Rietschel M, Schulze TG, Malzahn D**
Efficient region-based test strategy uncovers genetic risk factors for functional outcome in bipolar disorder.
Eur Neuropsychopharmacol. 2019 Jan;29(1):156-170. doi: 10.1016/j.euroneuro.2018.10.005. IF 3.853
32. **Bulubas L, Mezger E, Keeser D, Padberg F, Brunoni AR**
Novel Neuromodulatory Approaches for Depression: Neurobiological Mechanisms. In: Queredo J, Carvalho AF, Zarate CA (eds).
Neurobiology of Depression – Road to Novel Therapeutics. Elsevier, Academic Press, 2019, S. 347-360.
33. **Bulubas L, Padberg F, Bueno PV, Duran F, Busatto G, Amaro E Jr, Benseñor IM, Lotufo PA, Goerigk S, Gattaz W, Keeser D, Brunoni AR**
Antidepressant effects of tDCS are associated with prefrontal gray matter volumes at baseline: Evidence from the ELECT-TDCS trial
Brain Stimul. 2019 Sep - Oct;12(5):1197-1204. doi: 10.1016/j.brs.2019.05.006. IF 6.565
34. **Burgold J, Schulz-Trieglaff EK, Voelkl K, Gutiérrez-Ángel S, Bader JM, Hosp F, Mann M, Arzberger T, Klein R, Liebscher S, Dudanova I**
Cortical circuit alterations precede motor impairments in Huntington's disease mice. Sci Rep. 2019 Apr 29;9(1):6634. doi: 10.1038/s41598-019-43024-w. IF 3.998
35. **Buschert V, Prochazka D, Bartl H, Diemer J, Malchow B, Zwanzger P, Brunbauer A**
Effects of physical activity on cognitive performance: a controlled clinical study in depressive patients.
Eur Arch Psychiatry Clin Neurosci. 2019 Aug;269(5):555-563. doi: 10.1007/s00406-018-0916-0. IF 3.288
36. **Campana M, Papazova I, Pross B, Hasan A, Strube W**
Motor-cortex excitability and response variability following paired-associative stimulation: a proof-of-concept study comparing individualized and fixed inter-stimulus intervals.
Exp Brain Res. 2019 Jul;237(7):1727-1734. doi: 10.1007/s00221-019-05542-x. IF 1.591
37. **Chrobok A**
Phobischer Schwankschwindel. Update Diagnostik und Therapie.
Nervenheilkunde 2019; 38(8): 542-546. IF -

38. **Comes AL, Senner F, Budde M, Adorjan K, Anderson-Schmidt H, Andlauer TFM, Gade K, Hake M, Heilbronner U, Kalman JL, Reich-Erkelenz D, Klöhn-Saghatolislam F, Schaupp SK, Schulte EC, Juckel G, Dannlowski U, Schmauß M, Zimmermann J, Reimer J, Reininghaus E, Anghelescu IG, Arolt V, Baune BT, Konrad C, Thiel A, Fallgatter AJ, Nieratschker V, Figge C, von Hagen M, Koller M, Becker T, Wigand ME, Jäger M, Dietrich DE, Stierl S, Scherk H, Spitzer C, Folkerts H, Witt SH, Degenhardt F, Forstner AJ, Rietschel M, Nöthen MM, Wiltfang J, Falkai P, Schulze TG, Papiol S**
The genetic relationship between educational attainment and cognitive performance in major psychiatric disorders.
Transl Psychiatry. 2019 Aug 28;9(1):210. doi: 10.1038/s41398-019-0547-x. IF 5.280

39. **Cross-Disorder Group of the Psychiatric Genomics Consortium. Electronic address: plee0@mgm.harvard.edu; Cross-Disorder Group of the Psychiatric Genomics Consortium**
Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders
Cells. 2019 Dec 12;179(7):1469-1482.e11. doi: 10.1016/j.cell.2019.11.020. IF 4.366

40. **Czamara D, Eraslan G, Page CM, Lahti J, Lahti-Pulkkinen M, Hämäläinen E, Kajantie E, Laivuori H, Villa PM, Reynolds RM, Nystad W, Håberg SE, London SJ, O'Donnell KJ, Garg E, Meaney MJ, Entringer S, Wadhwa PD, Buss C, Jones MJ, Lin DTS, MacIsaac JL, Kobor MS, Koen N, Zar HJ, Koenen KC, Dalvie S, Stein DJ, Kondofersky I, Müller NS, Theis FJ; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Räikkönen K, Binder EB**
Integrated analysis of environmental and genetic influences on cord blood DNA methylation in new-borns.
Nat Commun. 2019 Jun 11;10(1):2548. doi: 10.1038/s41467-019-10461-0. IF 12.121

41. **da Silva RMF, Batistuzzo MC, Shavitt RG, Miguel EC, Stern E, Mezger E, Padberg F, D'Urso G, Brunoni AR**
Transcranial direct current stimulation in obsessive-compulsive disorder: an update in electric field modeling and investigations for optimal electrode montage.
Expert Rev Neurother. 2019 Oct;19(10):1025-1035. doi: 10.1080/14737175.2019.1637257. IF 3.743

42. **Das-Friebel A, Parkinson-Gloor N, Brand S, Dewald-Kaufmann JF, Grob A, Wolke D, Lemola S**
A pilot cluster-randomised study to increase sleep duration by decreasing electronic media use at night and caffeine consumption in adolescents.
Sleep Med. 2019 Aug;60:109-115. doi: 10.1016/j.sleep.2018.11.010. IF 3.038

43. **Dewald-Kaufmann J, de Bruin E, Michael G**
Cognitive Behavioral Therapy for Insomnia (CBT-i) in School-Aged Children and Adolescents.
Sleep Med Clin. 2019 Jun;14(2):155-165. doi: 10.1016/j.jsmc.2019.02.002. IF -

44. **Diemer J, Zwanzger P**
[Development of virtual reality as an exposure technique].
Nervenarzt. 2019 Jul;90(7):715-723. doi: 10.1007/s00115-019-0678-6. IF 0.824

45. **Druschky K, Bleich S, Grohmann R, Engel RR, Neyazi A, Stübner S, Toto S**
Seizure rates under treatment with antipsychotic drugs: Data from the AMSP project.
World J Biol Psychiatry. 2019 Nov;20(9):732-741. doi: 10.1080/15622975.2018.1500030. IF 4.164
46. **Duffy ME, Rogers ML, Joiner TE, Bergen AW, Berrettini W, Bulik CM, Brandt H, Crawford S, Crow S, Fichter M, Halmi K, Kaplan AS, Klump KL, Lilienfeld L, Magistretti PJ, Mitchell J, Schork NJ, Strober M, Thornton LM, Treasure J, Woodside B, Kaye WH, Keel PK**
An investigation of indirect effects of personality features on anorexia nervosa severity through interoceptive dysfunction in individuals with lifetime anorexia nervosa diagnoses.
Int J Eat Disord. 2019 Feb;52(2):200-205. doi: 10.1002/eat.23008. IF 3.668
47. **Endres D, Bechter K, Prüss H, Hasan A, Steiner J, Leyboldt F, Tebartz van Elst L**
[Autoantibody-associated schizophreniform psychoses: clinical symptomatology].
Nervenarzt. 2019 May;90(5):547-563. doi: 10.1007/s00115-019-0700-z. IF 0.824
48. **Engelbregt H, Meijburg N, Schulten M, Pogarell O, Deijen JB**
The Effects of Binaural and Monoaural Beat Stimulation on Cognitive Functioning in Subjects with Different Levels of Emotionality
Advances in Cognitive Psychology 2019; 15: 199-207. doi: 10.5709/acp-0268-8.
eCollection 2019. IF 1.200
49. **Falkai P, Schmitt A**
[Lithium therapy: Suicidality and neurobiological effects].
Fortschr Neurol Psychiatr. 2019; 87(1): 10-11. IF 0.642
50. **Falkai P, Schmitt A**
The need to develop personalized interventions to improve cognition in schizophrenia.
World Psychiatry. 2019 Jun;18(2):170. doi: 10.1002/wps.20650. IF 40.595
51. **Falter-Wagner CM, Vogeley K, Kraemer K**
Psycho- und Pharmakotherapie bei Autismus-Spektrum-Störungen im Erwachsenenalter.
Info Neurologie & Psychiatrie 2019; 21(11): 1-12. IF -
52. **Fichter MM**
Epidemiologie der Ess- und Fütterstörungen.
In: Herpertz S, Fichter M, Herpertz-Dahlmann A, Hilbert A, Tuschen-Caffier B, Vocks S, Zeeck A (Hrsg)
S3-Leitlinie Diagnostik und Behandlung der Essstörungen.
Springer, Heidelberg, New York, 2019.
53. **Fichter MM, Quadflieg N**
Outcomes of anorexic and bulimic eating disorders.
In: Hebebrand J; Herpertz-Dahlman Beate: Eating Disorders and Obesity in Children and Adolescents.
Elsevier, 2019, pp. 159-164.

54. **Fonteneau C, Mondino M, Arns M, Baeken C, Bikson M, Brunoni AR, Burke MJ, Neuvonen T, Padberg F, Pascual-Leone A, Poulet E, Ruffini G, Santarnecchi E, Sauvaget A, Schellhorn K, Suaud-Chagny MF, Palm U, Brunelin J**
Sham tDCS: A hidden source of variability? Reflections for further blinded, controlled trials.
Brain Stimul. 2019 May - Jun;12(3):668-673. doi: 10.1016/j.brs.2018.12.977. IF 6.565

55. **Fsranke ML, Lersner UV, Essel OQ, Adorjan K, Schomerus G, Gómez-Carrillo A, Tam Ta TM, Böge K, Mobashery M, Dettling M, Diefenbacher A, Angermeyer MC, Hahn E**
The relationship between causal beliefs and desire for social distance towards people with schizophrenia and depression: Results from a survey of young Ghanaian adults.
Psychiatry Res. 2019 Jan;271:220-225. doi: 10.1016/j.psychres.2018.11.030. IF 2.118

56. **Furukawa TA, Reijnders M, Kishimoto S, Sakata M, DeRubeis RJ, Dimidjian S, Dozois DJA, Hegerl U, Hollon SD, Jarrett RB, Lespérance F, Segal ZV, Mohr DC, Simons AD, Quilty LC, Reynolds CF, Gentili C, Leucht S, Engel RR, Cuijpers P**
Translating the BDI and BDI-II into the HAMD and vice versa with equipercentile linking.
Epidemiol Psychiatr Sci. 2019 Mar 14;29:e24. doi: 10.1017/S2045796019000088. IF 5.876

57. **Fusar-Poli P, Bauer M, Borgwardt S, Bechdolf A, Correll CU, Do KQ, Domschke K, Galderisi S, Kessing LV, Koutsouleris N, Krebs MO, Lennox B, McGuire P, Meyer-Lindenberg A, Millan MJ, Nieman D, Pfennig A, Sand M, Whenert A, van Amelsvoort T, Arango C**
European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP).
Eur Neuropsychopharmacol. 2019 Dec;29(12):1301-1311. doi: 10.1016/j.euroneuro.2019.09.006. IF 3.853

58. **Gallo V, Vineis P, Cancellieri M, Chiodini P, Barker RA, Brayne C, Pearce N, Vermeulen R, Panico S, Bueno-de-Mesquita B, Vanacore N, Forsgren L, Ramat S, Ardanaz E, Arriola L, Peterson J, Hansson O, Gavrila D, Sacerdote C, Sieri S, Kühn T, Katzke VA, van der Schouw YT, Kyrozi A, Masala G, Mattiello A, Perneczky R, Middleton L, Saracci R, Riboli E**
Exploring causality of the association between smoking and Parkinson's disease.
Int J Epidemiol. 2019 Jun 1;48(3):912-925. doi: 10.1093/ije/dyy230. IF 7.707

59. **Garbusow M, Nebe S, Sommer C, Kuitunen-Paul S, Sebold M, Schad DJ, Friedel E, Veer IM, Wittchen HU, Rapp MA, Ripke S, Walter H, Huys QJM, Schlagenhauf F, Smolka MN, Heinz A**
Pavlovian-To-Instrumental Transfer and Alcohol Consumption in Young Male Social Drinkers: Behavioral, Neural and Polygenic Correlates.
J Clin Med. 2019 Aug 8;8(8). pii: E1188. doi: 10.3390/jcm8081188. IF 3.303

60. **Gastberger S, Baumgartner MR, Soyka M, Quednow BB, Hulka LM, Herdener M, Seifritz E, Mutschler J**
Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.
Eur Addict Res 2019; 25(4): 207-212. doi: 10.1159/000500542. IF 2.269

61. **Georgescu AL, Koehler JC, Weiske J, Vogeley K, Koutsouleris N, Falter-Wagner CM**
Machine learning approaches to study social interaction difficulties in ASD.
Frontiers in Robotics and AI; 2019 Nov 29;6:132. doi: 10.3389/frobt.2019.00132.
eCollection 2019. IF -
62. **Gibbels C, Sinke C, Kneer J, Amelung T, Mohnke S, Beier KM, Walter H, Schiltz K, Gerwinn H, Pohl A, Ponseti J, Foedisch C, Ristow I, Walter M, Kaergel C, Massau C, Schiffer B, Kruger THC**
Two Sides of One Coin: A Comparison of Clinical and Neurobiological Characteristics of Convicted and Non-Convicted Pedophilic Child Sexual Offenders.
J Clin Med 2019; 8. pii: E947 doi: 10.3390/jcm8070947. IF 3.303
63. **Gottschalk MG, Richter J, Ziegler C, Schiele MA, Mann J, Geiger MJ, Schartner C, Homola GA, Alpers GW, Büchel C, Fehm L, Fydrich T, Gerlach AL, Gloster AT, Helbig-Lang S, Kalisch R, Kircher T, Lang T, Lonsdorf TB, Pané-Farré CA, Ströhle A, Weber H, Zwanzger P, Arolt V, Romanos M, Wittchen HU, Hamm A, Pauli P, Reif A, Deckert J, Neufang S, Höfler M, Domschke K**
Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes.
Transl Psychiatry 2019 Feb 4;9(1):75. doi: 10.1038/s41398-019-0415-8. IF 5.280
64. **Greil W, Zhang X, Stassen H, Grohmann R, Bridler R, Hasler G, Toto S, Bleich S, Kasper S**
Cutaneous adverse drug reactions to psychotropic drugs and their risk factors - a case-control study.
Eur Neuropsychopharmacol 2019; 29: 111-121. doi: 10.1016/j.euroneuro.2018.10.010. IF 3.853
65. **Greiner T, Schneider M, Regente J, Toto S, Bleich S, Grohmann R, Heinze M**
Priapism induced by various psychotropics: A case series.
World J Biol Psychiatry 2019; 20: 505-512. doi: 10.1080/15622975.2018.1520396. IF 4.164
66. **Grimm MJ, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Colosimo C, van Eimeren T, Kassubek J, Levin J, Meissner WG, Nilsson C, Oertel WH, Piot I, Poewe W, Wenning GK, Boxer A, Golbe LI, Josephs KA, Litvan I, Morris HR, Whitwell JL, Compta Y, Corvol JC, Lang AE, Rowe JB, Höglinger GU; Movement Disorder Society-endorsed PSP Study Group**
How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.
Mov Disord 2019; 34(8): 1228-1232. doi: 10.1002/mds.27666. IF 8.679
67. **Grimmer T, Goldhardt O, Yakushev I, Ortner M, Sorg C, Diehl-Schmid J, Förstl H, Kurz A, Perneczky R, Miners S**
Associations of Neprilysin Activity in CSF with Biomarkers for Alzheimer's Disease.
Neurodegener Dis 2019; 19: 43-50. doi: 10.1159/000500811. IF 2.418

68. **Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, Pallesen J, Agerbo E, Andreassen OA, Anney R, Awashti S, Belliveau R, Bettella F, Buxbaum JD, Bybjerg-Grauholm J, Bækvad-Hansen M, Cerrato F, Chambert K, Christensen JH, Churchhouse C, Dellenvall K, Demontis D, De Rubeis S, Devlin B, Djurovic S, Dumont AL, Goldstein JL, Hansen CS, Hauberg ME, Hollegaard MV, Hope S, Howrigan DP, Huang H, Hultman CM, Klei L, Maller J, Martin J, Martin AR, Moran JL, Nyegaard M, Nærland T, Palmer DS, Palotie A, Pedersen CB, Pedersen MG, dPoterba T, Poulsen JB, Pourcain BS, Qvist P, Rehnström K, Reichenberg A, Reichert J, Robinson EB, Roeder K, Roussos P, Saemundsen E, Sandin S, Satterstrom FK, Davey Smith G, Stefansson H, Steinberg S, Stevens CR, Sullivan PF, Turley P, Walters GB, Xu X; Autism Spectrum Disorder Working Group of the Psychiatric Genomics Consortium; BUPGEN; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium; 23andMe Research Team, Stefansson K, Geschwind DH, Nordentoft M, Hougaard DM, Werge T, Mors O, Mortensen PB, Neale BM, Daly MJ, Børglum AD**
Identification of common genetic risk variants for autism spectrum disorder.
 Identification of common genetic risk variants for autism spectrum disorder.
 Nat Genet. 2019 Mar;51(3):431-444. doi: 10.1038/s41588-019-0344-8. IF 27.603
69. **Hadera E, Salelew E, Girma E, Dehning S, Adorjan K, Tesfaye M**
 Magnitude and Associated Factors of Perceived Stigma among Adults with Mental Illness in Ethiopia.
 Psychiatry J. 2019 Mar 27;2019:8427561. doi: 10.1155/2019/8427561. eCollection IF -
70. **Hämmig R, Preuss UW, Soyka M**
 Cannabis.
 In: Soyka M, Batra A, Heinz A, Moggi F, Walter M (Hrsg.)
 Suchtmedizin.
 Elsevier, München, 2019, S. 143-175.
71. **Häuser W, Hoch E, Petzke F, Thomasius R, Radbruch L, Batra A, Sommer C, Havemann-Reinecke U**
 [Medicinal cannabis and cannabis-based medication: an appeal to physicians, journalists, health insurances, and politicians for their responsible handling].
 Schmerz. 2019 Oct;33(5):466-470. doi: 10.1007/s00482-019-00409-0. IF 0.964
72. **Hall W, Hoch E, Lorenzetti V**
 Cannabis use and mental health: risks and benefits.
 Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):1-3. doi: 10.1007/s00406-019-00986-2. IF 3.288
73. **Harold D, Connolly S, Riley BP, Kendler KS, McCarthy SE, McCombie WR, Richards A, Owen MJ, O'Donovan MC, Walters J; Wellcome Trust Case Control Consortium 2; Schizophrenia Working Group of the Psychiatric Genomics Consortium, Donohoe G, Gill M, Corvin A, Morris DW**
 Population-based identity-by-descent mapping combined with exome sequencing to detect rare risk variants for schizophrenia.
 Am J Med Genet B Neuropsychiatr Genet. 2019 Apr;180(3):223-231. doi: 10.1002/ajmg.b.32716. IF 3.387

74. **Hasan A, Bandelow B, Yatham LN, Berk M, Falkai P, Möller HJ, Kasper S; WFSBP Guideline Task Force Chairs**
WFSBP guidelines on how to grade treatment evidence for clinical guideline development.
World J Biol Psychiatry. 2019 Jan;20(1):2-16. doi: 10.1080/15622975.2018.1557346. IF 4.164
75. **Hauer L, Pikija S, Schulte EC, Sztriha LK, Nardone R, Sellner J**
Cerebrovascular manifestations of herpes simplex virus infection of the central nervous system: a systematic review.
J Neuroinflammation. 2019 Jan 29;16(1):19. doi: 10.1186/s12974-019-1409-4. IF 5.793
76. **Hendrikoff L, Kambeitz-Ilankovic L, Pryss R, Senner F, Falkai P, Pogarell O, Hasan A, Peters H**
Prospective acceptance of distinct mobile mental health features in psychiatric patients and mental health professionals.
J Psychiatr Res. 2019 Feb;109:126-132. doi: 10.1016/j.jpsychires.2018.11.025. IF 3.745
77. **Herring A, Münster Y, Akkaya T, Moghaddam S, Deinsberger K, Meyer J, Zahel J, Sanchez-Mendoza E, Wang Y, Hermann DM, Arztberger T, Teuber-Hanselmann S, Keyvani K**
Erratum to "Kallikrein-8 inhibition attenuates Alzheimer's disease pathology in mice" [Alzheimer's & Dementia 2016;12:1273-87].
Alzheimers Dement. 2019 Aug;15(8):1121. doi: 10.1016/j.jalz.2019.04.012. IF -
78. **Herbsleb M, Keller-Varady K, Wobrock T, Hasan A, Schmitt A, Falkai P, Gabriel HHW, Bär KJ, Malchow B**
The Influence of Continuous Exercising on Chronotropic Incompetence in Multi-Episode Schizophrenia.
Front Psychiatry. 2019 Mar 13;10:90. doi: 10.3389/fpsy.2019.00090. IF 2.849
79. **Herle M, Brieber D, Zellner L, Brunnauer A, Eder M**
Konzept eines Screenings zur Einschätzung der Fahreignung bei kognitiven Beeinträchtigungen.
Zeitschrift für Verkehrssicherheit 2019; 2: 139-141. IF -
80. **Herpertz S, Fichter M, Herpertz-Dahlmann A, Hilbert A, Tuschen-Caffier B, Vocks S, Zeeck A (Hrsg)**
S34-Leitlinie Diagnostik und Behandlung der Essstörungen.
Springer, Heidelberg, New York, 2019.
81. **Hessler JB, Heuser J, Schlegl S, Bauman T, Greetfeld M, Voderholzer U**
Impact of comorbid borderline personality disorder on inpatient treatment for bulimia nervosa: analysis of routine data.
Borderline Personal Disord Emot Dysregul. 2019 Jan 16;6:1. doi: 10.1186/s40479-018-0098-4. IF 2.067
82. **Hessler JB, Schlegl S, Greetfeld M, Voderholzer U**
Dimensions within 24 weight history indices and their association with inpatient treatment outcome in adults with anorexia nervosa: analysis of routine data.
J Eat Disord. 2019 Jun 10;7:19. doi: 10.1186/s40337-019-0249-z. IF 2.828

83. **Hilbert S, Goerigk S, Padberg F, Nadjiri A, Übleis A, Jobst A, Dewald-Kaufmann J, Falkai P, Bühner M, Naumann F, Sarubin N**
The Role of Self-Esteem in Depression: A Longitudinal Study.
Behav Cogn Psychother. 2019 Mar;47(2):244-250. doi: 0.1017/S1352465818000243. IF 1.657
84. **Hilbert S, McAssey M, Bühner M, Schwaferts P, Gruber M, Goerigk S, Taylor PCJ**
Right hemisphere occipital rTMS impairs working memory in visualizers but not in verbalizers.
Sci Rep. 2019 Apr 19;9(1):6307. doi: 10.1038/s41598-019-42733-6. IF 3.998
85. **Hoch E**
Substanzkonsumstörung: Psychologische Therapie bei Indikationen im Kindes- und Jugendalter.
In: Schneider S, Margraf J (Hrsg.) Lehrbuch der Verhaltenstherapie, Band 3. Springer, Berlin Heidelberg, 2019, S. 809-830.
86. **Hoch E**
Zwei Jahre „Cannabis-Gesetz“ in Deutschland – Alltag oder noch nicht? Two years of medical cannabis law in Germany – Is this already commonplace?
Sucht 2019; 65(3): 157-159. IF -
87. **Hoch E, Friemel CM, Schneider M**
Cannabis
Potenzial und Risiko. Eine wissenschaftliche Bestandsaufnahme
Springer, Berlin Heidelberg, 2019
88. **Hoch E, Friemel C, Schneider M, Pogarell O, Hasan A, Preuss UW; CaPRis-Projektgruppe**
[Efficacy and safety of medicinal cannabis: results of the CaPRis study].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.
2019 Jul;62(7):825-829. doi: 10.1007/s00103-019-02965-3. IF 1.059
89. **Hoch E, Gantner A**
Cannabisgebrauchsstörungen.
In: Schnell T., Schnell K. (eds)
Handbuch Klinische Psychologie 2019. Springer, Berlin Heidelberg, S. 1-12.
90. **Hoch E, Niemann D, von Keller R, Schneider M, Friemel CM, Preuss UW, Hasan A, Pogarell O**
How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review.
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):87-105. doi: 10.1007/s00406-019-00984-4. IF 3.288
91. **Hoch E, Niemann D, von Keller R, Schneider M, Friemel CM, Preuss UW, Hasan A, Pogarell O**
Correction to: How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review.
Eur Arch Psychiatry Clin Neurosci. 2019 Dec;269(8):995. doi: 10.1007/s00406-019-00999-x. IF -

92. **Hoch E, Preuss UW**
[Cannabis, Cannabinoids and Cannabis Use Disorders].
Fortschr Neurol Psychiatr. 2019 Dec;87(12):714-728. doi: 10.1055/a-1008-7427. IF 0.642
93. **Hoch E, Preuss UW**
Cannabis, Cannabinoide und Cannabiskonsumstörungen.
PSYCH up2date 2019; 13(05): 395-409. IF -
94. **Honnorat N, Dong A, Meisenzahl-Lechner E, Koutsouleris N, Davatzikos C**
Neuroanatomical heterogeneity of schizophrenia revealed by semi-supervised machine learning methods.
Schizophr Res. 2019 Dec;214:43-50. doi: 10.1016/j.schres.2017.12.008. IF 3.759
95. **Hooshmand B, Rusanen M, Ngandu T, Leiviskä J, Sindi S, von Arnim CAF, Falkai P, Soininen H, Tuomilehto J, Kivipelto M**
Serum Insulin and Cognitive Performance in Older Adults: A Longitudinal Study.
Am J Med. 2019 Mar;132(3):367-373. doi: 10.1016/j.amjmed.2018.11.013. IF 4.529
96. **Hopfner F, Müller SH, Steppat D, Miller J, Schmidt N, Wandinger KP, Leyboldt F, Berg D, Franke A, Lieb W, Tittmann L, Balzer-Geldsetzer M, Baudrexel S, Dodel R, Hilker-Roggendorf R, Kalbe E, Kassubek J, Klockgether T, Liepelt-Scarfone I, Mollenhauer B, Neuser P, Reetz K, Riedel O, Schulte C, Schulz JB, Spottke A, Storch A, Trenkwalder C, Wittchen HU, Witt K, Wüllner U, Deuschl G, Kühlenbäumer G**
No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors.
Transl Neurodegener. 2019 Apr 3;8:11. doi: 10.1186/s40035-019-0153-0. IF 5.551
97. **Huckins LM, Dobbyn A, Ruderfer DM, Hoffman G, Wang W, Pardiñas AF, Rajagopal VM, Als TD, T Nguyen H, Girdhar K, Boocock J, Roussos P, Fromer M, Kramer R, Domenici E, Gamazon ER, Purcell S; CommonMind Consortium; Schizophrenia Working Group of the Psychiatric Genomics Consortium; iPSYCH-GEMS Schizophrenia Working Group, Demontis D, Børglum AD, Walters JTR, O'Donovan MC, Sullivan P, Owen MJ, Devlin B, Sieberts SK, Cox NJ, Im HK, Sklar P, Stahl EA**
Gene expression imputation across multiple brain regions provides insights into schizophrenia risk.
Nat Genet. 2019 Apr;51(4):659-674. doi: 10.1038/s41588-019-0364-4. IF 27.603
98. **Huckins LM, Dobbyn A, Ruderfer DM, Hoffman G, Wang W, Pardiñas AF, Rajagopal VM, Als TD, T Nguyen H, Girdhar K, Boocock J, Roussos P, Fromer M, Kramer R, Domenici E, Gamazon ER, Purcell S; CommonMind Consortium; Schizophrenia Working Group of the Psychiatric Genomics Consortium; iPSYCH-GEMS Schizophrenia Working Group, Demontis D, Børglum AD, Walters JTR, O'Donovan MC, Sullivan P, Owen MJ, Devlin B, Sieberts SK, Cox NJ, Im HK, Sklar P, Stahl EA**
Publisher Correction: Gene expression imputation across multiple brain regions provides insights into schizophrenia risk.
Nat Genet. 2019 Jun;51(6):1068. doi: 10.1038/s41588-019-0435-6. IF -

99. **Intaité M, Georgescu AL, Noreika V, von Saldern MA, Vogeley K, Falter-Wagner CM**
Adults with autism spectrum condition have atypical perception of ambiguous figures when bottom-up and top-down interactions are incongruous.
Autism. 2019 Jul;23(5):1133-1142. doi: 10.1177/1362361318782221. IF 4.609
100. **Kästner D, Buchholz I, Weigel A, Brunner R, Voderholzer U, Gumz A, Löwe B**
Facilitators and barriers in anorexia nervosa treatment initiation (FABIANA): study protocol for a mixed-methods and multicentre study.
BJPsych Open. 2019 Oct 21;5(6):e92. doi: 10.1192/bjo.2019.77. IF 2.286
101. **Kaiser N, Seves M, Koutsouleris N, Ruhrmann S**
Validation of a German Version of the Resilience Scale for Adults (RSA).
Diagnostica 2019; 65: 205-215. IF 0.488
102. **Kalman JL, Papiol S, Forstner AJ, Heilbronner U, Degenhardt F, Strohmaier J, Adli M, Adorjan K, Akula N, Alda M, Anderson-Schmidt H, Andlauer TF, Anghelescu IG, Ardau R, Arias B, Arolt V, Aubry JM, Backlund L, Bartholdi K, Bauer M, Baune BT, Becker T, Bellivier F, Benabarre A, Bengesser S, Bhattacharjee AK, Biernacka JM, Birner A, Brichant-Petitjean C, Budde M, Cervantes P, Chillotti C, Cichon S, Clark SR, Colom F, Comes AL, Cruceanu C, Czerski PM, Dannlowski U, Dayer A, Del Zompo M, DePaulo JR, Dietrich DE, Étain B, Ethofer T, Falkai P, Fallgatter A, Figge C, Flatau L, Folkerts H, Frisen L, Frye MA, Fullerton JM, Gade K, Gard S, Garnham JS, Goes FS, Grigoriu-Serbanescu M, Gryaznova A, Hake M, Hauser J, Herms S, Hoffmann P, Hou L, Jäger M, Jamain S, Jiménez E, Juckel G, Kahn JP, Kassem L, Kelsoe J, Kittel-Schneider S, Kliwicksi S, Klohn-Sagatholislam F, Koller M, König B, Konrad C, Lackner N, Laje G, Landén M, Lang FU, Lavebratt C, Leboyer M, Leckband SG, Maj M, Manchia M, Martinsson L, McCarthy MJ, McElroy SL, McMahon FJ, Mitchell PB, Mitjans M, Mondimore FM, Monteleone P, Nieratschker V, Nievergelt CM, Novák T, Ösby U, Pfennig A, Potash JB, Reich-Erkelenz D, Reif A, Reimer J, Reininghaus E, Reitt M, Ripke S, Rouleau GA, Rybakowski JK, Schalling M, Scherk H, Schmauß M, Schofield PR, Schubert KO, Schulte EC, Schulz S, Senner F, Severino G, Shekhtman T, Shilling PD, Simhandl C, Slaney CM, Spitzer C, Squassina A, Stamm T, Stegmaier S, Stierl S, Stopkova P, Thiel A, Tighe SK, Tortorella A, Turecki G, Vieta E, Veeh J, von Hagen M, Wigand ME, Wiltfang J, Witt S, Wright A, Zandi PP, Zimmermann J, Nöthen M, Rietschel M, Schulze TG**
Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study.
Bipolar Disord. 2019 Feb;21(1):68-75. doi: 10.1111/bdi.12659. IF 5.410
103. **Kambeitz-Ilankovic L, Betz LT, Dominke C, Haas SS, Subramaniam K, Fisher M, Vinogradov S, Koutsouleris N, Kambeitz J**
Multi-outcome meta-analysis (MOMA) of cognitive remediation in schizophrenia: Revisiting the relevance of human coaching and elucidating interplay between multiple outcomes.
Neurosci Biobehav Rev. 2019 Dec;107:828-845.
doi:10.1016/j.neubiorev.2019.09.031. IF 8.330
104. **Kambeitz-Ilankovic L, Haas SS, Meisenzahl E, Dwyer DB, Weiske J, Peters H, Möller HJ, Falkai P, Koutsouleris N**
Neurocognitive and neuroanatomical maturation in the clinical high-risk states for psychosis: A pattern recognition study.
Neuroimage Clin. 2019;21:101624. doi: 10.1016/j.nicl.2018.101624. IF 4.350

105. **Kamp D, Engelke C, Wobrock T, Wölwer W, Winterer G, Schmidt-Kraepelin C, Gaebel W, Langguth B, Landgrebe M, Eichhammer P, Frank E, Hajak G, Ohmann C, Verde PE, Rietschel M, Raees A, Honer WG, Malchow B, Schneider-Axmann T, Falkai P, Hasan A, Cordes J**
Left prefrontal high-frequency rTMS may improve movement disorder in schizophrenia patients with predominant negative symptoms - A secondary analysis of a sham-controlled, randomized multicenter trial.
Schizophr Res. 2019 Feb;204:445-447. doi: 10.1016/j.schres.2018.09.017. IF 3.759
106. **Kamp F, Proebstl L, Hager L, Schreiber A, Riebschläger M, Neumann S, Straif M, Schacht-Jablonowsky M, Manz K, Soyka M, Koller G**
Effectiveness of methamphetamine abuse treatment: Predictors of treatment completion and comparison of two residential treatment programs.
Drug Alcohol Depend. 2019 Aug 1;201:8-15. doi: 10.1016/j.drugalcdep.2019.04.010. IF 3.951
107. **Kamp F, Proebstl L, Penzel N, Adorjan K, Ilankovic A, Pogarell O, Koller G, Soyka M, Falkai P, Koutsouleris N, Kambeitz J**
Effects of sedative drug use on the dopamine system: a systematic review and meta-analysis of in vivo neuroimaging studies.
Neuropsychopharmacology. 2019 Mar;44(4):660-667. doi: 10.1038/s41386-018-0191-9. IF 6.751
108. **Kapogiannis D, Dobrowolny H, Tran J, Mustapic M, Frodl T, Meyer-Lotz G, Schiltz K, Schanze D, Rietschel M, Bernstein HG, Steiner J**
Insulin-signaling abnormalities in drug-naïve first-episode schizophrenia: Transduction protein analyses in extracellular vesicles of putative neuronal origin.
Eur Psychiatry. 2019 Oct;62:124-129. doi: 10.1016/j.eurpsy.2019.08.012. IF 4.464
109. **Karch S, Paolini M, Gschwendtner S, Jeanty H, Reckenfelderbäumer A, Yaseen O, Maywald M, Fuchs C, Rauchmann BS, Chrobok A, Rabenstein A, Ertl-Wagner B, Pogarell O, Keeser D, Rütger**
Real-Time fMRI Neurofeedback in Patients With Tobacco Use Disorder During Smoking Cessation: Functional Differences and Implications of the First Training Session in Regard to Future Abstinence or Relapse.
Front Hum Neurosci. 2019 Mar 4;13:65. doi: 10.3389/fnhum.2019.00065. IF 2.673
110. **Karch S, Paolini M, Jeanty H, Reckenfelderbäumer A, Gschwendtner S, Maywald M, Rauchmann BS, Rabenstein A, Chrobok A, Gertzen M, Ertl-Wagner B, Pogarell O, Rütger T, Keeser D**
Neurofeedback mithilfe funktioneller Magnetresonanztomographie in Echtzeit (rtfMRT) bei Patienten mit psychischen Erkrankungen: klinisches Anwendungspotenzial im Bereich der Emotionsregulation und des emotionalen Erlebens.
Psychotherapeut 2019; 64(3): 212-219. IF 0.462
111. **Karow A, Holtmann M, Koutsouleris N, Pfennig A, Resch F**
[Psychotic disorders in the transition phase: early detection and early intervention].
Fortschr Neurol Psychiatr. 2019 Nov;87(11):629-633. doi: 10.1055/a-1025-1994. IF 0.642
112. **Kirsch V, Boegle R, Keeser D, Kierig E, Ertl-Wagner B, Brandt T, Dieterich M**
Beyond binary parcellation of the vestibular cortex - A dataset.
Data Brief. 2019 Jan 22;23:103666. doi: 10.1016/j.dib.2019.01.014. IF -

113. **Kneer J, Borchardt V, Kärgel C, Sinke C, Massau C, Tenbergen G, Ponseti J, Walter H, Beier KM, Schiffer B, Schiltz K, Walter M, Kruger THC**
Diminished fronto-limbic functional connectivity in child sexual offenders.
J Psychiatr Res. 2019 Jan;108:48-56. doi: 10.1016/j.jpsychires.2018.01.012. IF 3.745
114. **Koller G, Schwarzer A, Halfter K, Soyka M**
Pain management in opioid maintenance treatment.
Expert Opin Pharmacother. 2019 Nov;20(16):1993-2005. doi: 10.1080/14656566.2019.1652270. IF 2.878
115. **Koller G, Walcher S, Adorjan K**
Schmerzbehandlung bei Substitution, ein Praxisbericht.
Suchtmed 2019; 21: 331-337. IF -
116. **Koller G, Zill P, Soyka M, Adorjan K, Weiss C, Kern A, Nguyen-Thien ML, Kamp F, Proebstl L, Krause D, Ruhdorfer S, Bergmann W, Preuss UW**
Short-term changes in global methylation and hydroxymethylation during alcohol detoxification.
Eur Neuropsychopharmacol. 2019 Jul;29(7):897-903. doi: 10.1016/j.euroneuro.2019.05.001. IF 3.853
117. **Koutsouleris N, Upthegrove R, Wood SJ**
Importance of Variable Selection in Multimodal Prediction Models in Patients at Clinical High Risk for Psychosis and Recent Onset Depression-Reply.
JAMA Psychiatry. 2019 Mar 1;76(3):339-340. doi: 10.1001/jamapsychiatry.2018.4237. IF 17.471
118. **Krammer S, Grosse Holtforth M, Soyka M, Liebreinz M**
Erfassung der komplexen posttraumatischen Belastungsstörung mit dem revidierten Trauma Symptom Inventory (TSI-2).
Fortschr Neurol Psychiatr. 2019 Jun;87(6):364-371. doi: 10.1055/s-0044-101034. IF 0.642
119. **Kranaster L, Hoyer C, Aksay SS, Bumb JM, Müller N, Zill P, Schwarz MJ, Moll N, Lutz B, Bindila L, Zerr I, Schmitz M, Blennow K, Zetterberg H, Haffner D, Leifheit-Nestler M, Ozbalci C, Janke C, Thiel M, Sartorius A**
Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study.
Neuropsychobiology. 2019;77(1):13-22. doi: 10.1159/000491401. IF 1.694
120. **Kratzer L, Heinz P, Schennach R, Schiepek GK, Padberg F, Jobst A**
Stationäre Therapie der komplexen PTBS in Folge körperlicher oder sexualisierter Gewalt in der Kindheit: Wirksamkeit und Prädiktoren des Behandlungsverlaufs.
Psychother Psychosom Med Psychol. 2019 Mar;69(3-04):114-122. doi: 10.1055/a-0591-3962. IF 1.051
121. **Krause D, Jobst A, Langemak SM, Keeser D, Chrobok AI, Langgartner S, Adorjan K, Gertzen M, Pogarell O, Karch S**
Event-Related Potentials Are Associated With Unexpected Gain and Loss: Using a Gambling Paradigm.
Clin EEG Neurosci. 2019 May;50(3):154-160. doi: 10.1177/1550059418814987. IF 1.765

122. **Kruger THC, Sinke C, Kneer J, Tenbergen G, Khan AQ, Burkert A, Müller-Engling L, Engler H, Gerwinn H, von Wurmb-Schwark N, Pohl A, Weiß S, Amelung T, Mohnke S, Massau C, Kärgel C, Walter M, Schiltz K, Beier KM, Ponseti J, Schiffer B, Walter H, Jahn K, Frieling H**
Child sexual offenders show prenatal and epigenetic alterations of the androgen system.
Transl Psychiatry. 2019 Jan 18;9(1):28. doi: 10.1038/s41398-018-0326-0. IF 5.280
123. **Kruger THC, Sinke C, Kneer J, Tenbergen G, Khan AQ, Burkert A, Müller-Engling L, Engler H, Gerwinn H, von Wurmb-Schwark N, Pohl A, Weiß S, Amelung T, Mohnke S, Massau C, Kärgel C, Walter M, Schiltz K, Beier KM, Ponseti J, Schiffer B, Walter H, Jahn K, Frieling H**
Author correction: Child sexual offenders show prenatal and epigenetic alterations of the androgen system.
Transl Psychiatry. 2019 Feb 18;9(1):95. doi: 10.1038/s41398-019-0417-6. IF -
124. **Kuitunen-Paul S, Obst E, Schmidt R, Sommer C, Kuitunen PT, Wittchen HU, Zimmermann US**
Effects of alcohol intoxication on self-reported drinking patterns, expectancies, motives and personality: a randomized controlled experimental study.
Addict Biol. 2019 May;24(3):522-530. doi: 10.1111/adb.12604. IF 4.121
125. **Kuschefski M, Falter-Wagner CM, Bente G, Vogeley K, Georgescu AL**
Inferring power and dominance from dyadic nonverbal interactions in autism spectrum disorder.
Autism Res. 2019 Mar;12(3):505-516. doi: 10.1002/aur.2069. IF 3.727
126. **Lago SG, Tomasik J, van Rees GF, Steeb H, Cox DA, Rustogi N, Ramsey JM, Bishop JA, Petryshen T, Haggarty SJ, Vázquez-Bourgon J, Papiol S, Suarez-Pinilla P, Crespo-Facorro B, van Beveren NJ, Bahn S**
Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo.
Sci Adv. 2019 May 8;5(5):eaau9093. doi: 10.1126/sciadv.aau9093. IF 13.116
127. **Laux G, Brunnauer A, Graw M**
Fahreignung bei psychischen Erkrankungen. Verkehrsmedizin und Verkehrspsychologie.
MWV, Bonn, 2019.
128. **Levinson CA, Zerwas SC, Brosf LC, Thornton LM, Strober M, Pivarunas B, Crowley JJ, Yilmaz Z, Berrettini WH, Brandt H, Crawford S, Fichter MM, Halmi KA, Johnson C, Kaplan AS, La Via M, Mitchell J, Rotondo A, Woodside DB, Kaye WH, Bulik CM**
Associations between dimensions of anorexia nervosa and obsessive-compulsive disorder: An examination of personality and psychological factors in patients with anorexia nervosa.
Eur Eat Disord Rev. 2019 Mar;27(2):161-172. doi: 10.1002/erv.2635. IF 3.560
129. **Liu J, Heinsen H, Grinberg LT, Alho E, Amaro E Jr, Pasqualucci CA, Rüb U, Seidel K, den Dunnen W, Arzberger T, Schmitz C, Kiessling MC, Bader B, Danek A**
Pathoarchitectonics of the cerebral cortex in chorea-acanthocytosis and Huntington's disease.
Neuropathol Appl Neurobiol. 2019 Apr;45(3):230-243. doi: 10.1111/nan.12495. IF 7.500

130. **Löhrs L, Hasan A**
[Risk factors for the development of schizophrenia].
Fortschr Neurol Psychiatr. 2019 Feb;87(2):133-143. doi: 10.1055/a-0836-7839. IF 0.642
131. **Makino Y, Jensen NH, Yokota N, Rossner MJ, Akiyama H, Shirahige K, Okada Y**
Single cell RNA-sequencing identified Dec2 as a suppressive factor for spermatogonial differentiation by inhibiting Sohlh1 expression.
Sci Rep. 2019 Apr 15;9(1):6063. doi: 10.1038/s41598-019-42578-z. IF 3.998
132. **Maron J, Gomes de Matos E, Piontek D, Kraus L, Pogarell O**
Exploring socio-economic inequalities in the use of medicines: is the relation mediated by health status?
Public Health 2019; 169: 1-9. doi: 10.1016/j.puhe.2018.12.018. IF 1.774
133. **Martini J, Bauer M, Lewitzka U, Voss C, Pfennig A, Ritter D, Wittchen HU**
Predictors and outcomes of suicidal ideation during peripartum period.
J Affect Disord. 2019 Oct 1;257:518-526. doi: 10.1016/j.jad.2019.07.040. IF 3.892
134. **Maurus I, Hasan A, Röh A, Takahashi S, Rauchmann B, Keeser D, Malchow B, Schmitt A, Falkai P**
Neurobiological effects of aerobic exercise, with a focus on patients with schizophrenia.
Eur Arch Psychiatry Clin Neurosci. 2019 Aug;269(5):499-515. doi: 10.1007/s00406-019-01025-w. IF 3.288
135. **Maurus I, Röh A, Falkai P, Malchow B, Schmitt A, Hasan A**
Nonpharmacological treatment of dyscognition in schizophrenia: effects of aerobic exercise.
Dialogues Clin Neurosci. 2019 Sep;21(3):261-269. doi: 10.31887/DCNS.2019.21.3/aschmitt. IF 5.397
136. **Meule A, Gearhardt AN**
Ten years of the Yale Food Addiction Scale: a review of version 2.0
Curr Addict Rep 2019; 6: 218-228. IF -
137. **Meule A, Holzapfel C, Brandl B, Greetfeld M, Hessler-Kaufmann JB, Skurk T, Quadflieg N, Schlegl S, Hauner H, Voderholzer U**
Measuring orthorexia nervosa: A comparison of four self-report questionnaires.
Appetite. 2020 Mar 1;146:104512. doi: 10.1016/j.appet.2019.104512. IF 3.608
138. **Meule A, Richard A, Dinic R, Blechert J**
Effects of a Smartphone-Based Approach-Avoidance Intervention on Chocolate Craving and Consumption: Randomized Controlled Trial.
JMIR Mhealth Uhealth. 2019 Nov 1;7(11):e12298. doi: 10.2196/12298. IF 4.313
139. **Midani-Kurçak JS, Dinekov M, Puladi B, Arzberger T, Köhler C**
Effect of tau-pathology on charged multivesicular body protein 2b (CHMP2B).
Brain Res. 2019 Mar 1;1706:224-236. doi: 10.1016/j.brainres.2018.11.008. IF 2.733

140. **Miebach L, Wolfsgruber S, Polcher A, Peters O, Menne F, Luther K, Incesoy E, Priller J, Spruth E, Altenstein S, Buerger K, Catak C, Janowitz D, Perneczky R, Utecht J, Laske C, Buchmann M, Schneider A, Fliessbach K, Kalbhen P, Heneka MT, Brosseon F, Spottke A, Roy N, Teipel SJ, Kilimann I, Wiltfang J, Bartels C, Düzel E, Dobisch L, Metzger C, Meiberth D, Ramirez A, Jessen F, Wagner M**
Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study.
Alzheimers Res Ther. 2019 Jul 31;11(1):66. doi: 10.1186/s13195-019-0515-y. IF 6.116
141. **Möller HJ**
Medikamentöse Depressionsbehandlung überraschend im Aufwind?
Psychopharmakotherapie 2019; 26: 313-314. IF -
142. **Möller HJ**
Rückblick auf ein Vierteljahrhundert PPT.
Psychopharmakotherapie 2019; 26: 1. IF -
143. **Möller HJ, Leucht S**
Weiterbildungs-Curriculum Psychopharmakologie/Pharmakotherapie. Teil 6: Evidenzbasierung und Leitlinien in der Psychopharmaka-Therapie in der Psychiatrie.
Psychopharmakotherapie 2019; 26: 45-56. IF -
144. **Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S**
Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials.
Eur Arch Psychiatry Clin Neurosci. 2019 Mar;269(2):183-193. doi: 10.1007/s00406-017-0852-4. IF 3.288
145. **Möller-Leimkühler AM**
Geschlechterspezifische Aspekte psychischer Störungen.
Public Health Forum 2019; 27: 139-142. IF -
146. **Möller-Leimkühler AM**
Why is terrorism a man's business?
In: Mazaritti D, Stahl SM (ed). Evil, Terrorism & Psychiatry. Cambridge University Press 2019, pp 49-67.
147. **Monteleone AM, Fernandez-Aranda F, Voderholzer U**
Evidence and perspectives in eating disorders: a paradigm for a multidisciplinary approach.
World Psychiatry. 2019 Oct;18(3):369-370. doi: 10.1002/wps.20687. IF 40.595
148. **Moritz S, Külz A, Voderholzer U, Hillebrand T, McKay D, Jelinek L**
"Phobie à deux" and other reasons why clinicians do not apply exposure with response prevention in patients with obsessive-compulsive disorder.
Cogn Behav Ther. 2019 Mar;48(2):162-176. doi: 10.1080/16506073.2018.1494750. IF 4.413

149. **Morya E, Monte-Silva K, Bikson M, Esmaeilpour Z, Biazoli CE Jr, Fonseca A, Bocci T, Farzan F, Chatterjee R, Hausdorff JM, da Silva Machado DG, Brunoni AR, Mezger E, Moscaleski LA, Pegado R, Sato JR, Caetano MS, Sá KN, Tanaka C, Li LM, Baptista AF, Okano AH**
Beyond the target area: an integrative view of tDCS-induced motor cortex modulation in patients and athletes.
J Neuroeng Rehabil. 2019 Nov 15;16(1):141. doi: 10.1186/s12984-019-0581-1. IF 3.519
150. **Müller N**
COX-2 Inhibitors, Aspirin, and Other Potential Anti-Inflammatory Treatments for Psychiatric Disorders.
Front Psychiatry. 2019 May 31;10:375. doi: 10.3389/fpsyt.2019.00375. IF 2.849
151. **Müller N**
The Role of Intercellular Adhesion Molecule-1 in the Pathogenesis of Psychiatric Disorders.
Front Pharmacol. 2019 Nov 22;10:1251. doi: 10.3389/fphar.2019.01251. IF 4.225
152. **Müller N, Krause D, Barth R, Myint AM, Weidinger E, Stettinger W, Zill P, Drexhage H, Schwarz MJ**
Childhood Adversity and Current Stress are related to Pro- and Anti-inflammatory Cytokines in Major Depression.
J Affect Disord. 2019 Jun 15;253:270-276. doi: 10.1016/j.jad.2019.04.088. IF 3.892
153. **Müller TJ, Schiltz K**
Sucht und Forensik.
In: Soyka M, Batra A, Heinz A, Moggi F, Walter M (Hrsg.)
Suchtmedizin.
Elsevier, München, 2019, S. 407-427.
154. **Müller WE, Eckert A, Eckert GP, Fink H, Friedland K, Gauthier S, Hoerr R, Ihl R, Kasper S, Möller HJ**
Therapeutic efficacy of the Ginkgo special extract EGb761® within the framework of the mitochondrial cascade hypothesis of Alzheimer's disease.
World J Biol Psychiatry. 2019 Mar;20(3):173-189. doi: 10.1080/15622975.2017.1308552. IF 4.164
155. **Mutschler J, Müller CA, Soyka M**
Alkohol.
In: Soyka M, Batra A, Heinz A, Moggi F, Walter M (Hrsg.)
Suchtmedizin.
Elsevier, München, 2019, S. 93-119.
156. **Naab S, Fumi M, Schlegl S, Voderholzer U**
Stationäre Behandlung von Kindern und Jugendlichen mit Anorexia nervosa und Bulimia nervosa.
Kindheit und Entwicklung 2019; 28: 230-241. IF 1.404
157. **Neumann S, Franke AG, Soyka M**
Pharmakologisches Neuroenhancement mit Psychostimulanzien und artverwandten psychotropen Substanzen.
Internistische Praxis 2019; 60: 501-510. IF -

158. **Neumann S, Soyka M, Franke AG**
 Psychosocial health and prevention of crisis in rural areas – Results of a pilot panel on psychosocial problems, subjective burden, and utilization of help in Germany. *Mental Health & Prevention* 2019; 14: 200161. IF -
159. **Neumayr C, Voderholzer U, Tregarthen J, Schlegl S**
 Improving aftercare with technology for anorexia nervosa after intensive inpatient treatment: A pilot randomized controlled trial with a therapist-guided smartphone app. *Int J Eat Disord*. 2019 Oct;52(10):1191-1201. doi: 10.1002/eat.23152. IF 3.668
160. **Ogunyankin F, Nichols H, Park S, Falkai P**
 Effects of exercise-based interventions in severe mental illness: a feasibility study. *Eur Arch Psychiatry Clin Neurosci*. 2019 Aug;269(5):621-622. doi: 10.1007/s00406-018-0864-8. IF 3.288
161. **Ower C, Kemmler G, Vill T, Martini C, Schmitt A, Sperner-Unterwieser B, Hüfner K**
 The effect of physical activity in an alpine environment on quality of life is mediated by resilience in patients with psychosomatic disorders and healthy controls. *Eur Arch Psychiatry Clin Neurosci*. 2019 Aug;269(5):543-553. doi: 10.1007/s00406-018-0930-2. IF 3.288
162. **Palm U, Falkai P**
 [When exhaustion becomes a torment - from excessive labour to burn-out]. *Von der beruflichen Überarbeitung zum Burnout. "Ich bin total erschöpft". MMW Fortschr Med*. 2019 Mar;161(5):44-46. doi: 10.1007/s15006-019-0273-6. IF -
163. **Palm U, Goerigk S, Kirsch B, Bäuml L, Sarubin N, Hasan A, Brunoni AR, Padberg F**
 Treatment of major depression with a two-step tDCS protocol add-on to SSRI: Results from a naturalistic study. *Brain Stimul*. 2019 Jan - Feb;12(1):195-197. doi: 10.1016/j.brs.2018.10.003. IF 6.565
164. **Palm U, Kirsch V, Kübler H, Sarubin N, Keeser D, Padberg F, Dieterich M**
 Transcranial direct current stimulation (tDCS) for treatment of phobic postural vertigo: an open label pilot study. *Eur Arch Psychiatry Clin Neurosci*. 2019 Mar;269(2):269-272. doi: 10.1007/s00406-018-0894-2. IF 3.288
165. **Palm U, Kreuzer P, Langguth B, Padberg F**
 Hirnstimulationsverfahren zur Depressionsbehandlung. Betroffene Hirnregionen gezielt modulieren. *DNP – Der Neurologe und Psychiater* 2019; 20: 27-34. IF -
166. **Papiol S, Keeser D, Hasan A, Schneider-Axmann T, Raabe F, Degenhardt F, Rossner MJ, Bickelböller H, Cantuti-Castelvetri L, Simons M, Wobrock T, Schmitt A, Malchow B, Falkai P**
 Polygenic burden associated to oligodendrocyte precursor cells and radial glia influences the hippocampal volume changes induced by aerobic exercise in schizophrenia patients. *Transl Psychiatry*. 2019 Nov 11;9(1):284. doi: 10.1038/s41398-019-0618-z. IF 5.280

167. **Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, Müller SA, Colombo A, Monasor LS, Tahirovic S, Herms J, Willem M, Pettkus N, Butovsky O, Bartenstein P, Edbauer D, Rominger A, Ertürk A, Grathwohl SA, Neher JJ, Holtzman DM, Meyer-Luehmann M, Haass C**
Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE.
Nat Neurosci. 2019 Feb;22(2):191-204. doi: 10.1038/s41593-018-0296-9. IF 20.071
168. **Perneczky R**
Dementia prevention and reserve against neurodegenerative disease.
Dialogues Clin Neurosci 2019; 21(1): 53-60. doi: 10.31887/DCNS.2019.21.1/rperneczky2. IF 5.397
169. **Perneczky R**
Dementia treatment versus prevention.
Dialogues Clin Neurosci 2019; 21(1): 43-51. doi: 10.31887/DCNS.2019.21.1/rperneczky. IF 5.397
170. **Perneczky R, Kempermann G, Korczyn AD, Matthews FE, Ikram MA, Scarmeas N, Chetelat G, Stern Y, Ewers M**
Translational research on reserve against neurodegenerative disease: consensus report of the International Conference on Cognitive Reserve in the Dementias and the Alzheimer's Association Reserve, Resilience and Protective Factors Professional Interest Area working groups.
BMC Med. 2019 Feb 27;17(1):47. doi: 10.1186/s12916-019-1283-z. IF 6.782
171. **Peters L, Soyka**
Interrelationship of Opioid Dependence, Impaired Impulse Control, and Depressive Symptoms: An Open-Label Cross-Sectional Study of Patients in Maintenance Therapy.
Neuropsychobiology. 2019;77(2):73-82. doi: 10.1159/000494697. IF 1.694
172. **Peterson DL, Webb CA, Keeley JW, Gaebel W, Zielasek J, Rebello TJ, Robles R, Matsumoto C, Kogan CS, Kulygina M, Farooq S, Green MF, Falkai P, Hasan A, Galderisi S, Larach V, Krasnov V, Reed GM**
The reliability and clinical utility of ICD-11 schizoaffective disorder: A field trial.
Schizophr Res. 2019 Jun;208:235-241. doi: 10.1016/j.schres.2019.02.011. IF 3.759
173. **Plans L, Barrot C, Nieto E, Rios J, Schulze TG, Papiol S, Mitjans M, Vieta E, Benabarre A**
Association between completed suicide and bipolar disorder: A systematic review of the literature.
J Affect Disord. 2019 Jan 1;242:111-122. doi: 10.1016/j.jad.2018.08.054. IF 3.892
174. **Popovic D, Schmitt A, Kaurani L, Senner F, Papiol S, Malchow B, Fischer A, Schulze TG, Koutsouleris N, Falkai P**
Childhood Trauma in Schizophrenia: Current Findings and Research Perspectives.
Front Neurosci. 2019 Mar 21;13:274. doi: 10.3389/fnins.2019.00274. IF 3.707

175. **Pottier C, Ren Y, Perkerson RB 3rd, Baker M, Jenkins GD, van Blitterswijk M, DeJesus-Hernandez M, van Rooij JGJ, Murray ME, Christopher E, McDonnell SK, Fogarty Z, Batzler A, Tian S, Vicente CT, Matchett B, Karydas AM, Hsiung GR, Seelaar H, Mol MO, Finger EC, Graff C, Öijersted L, Neumann M, Heutink P, Synofzik M, Wilke C, Prudlo J, Rizzu P, Simon-Sanchez J, Edbauer D, Roeber S, Diehl-Schmid J, Evers BM, King A, Mesulam MM, Weintraub S, Geula C, Bieniek KF, Petrucelli L, Ahern GL, Reiman EM, Woodruff BK, Caselli RJ, Huey ED, Farlow MR, Grafman J, Mead S, Grinberg LT, Spina S, Grossman M, Irwin DJ, Lee EB, Suh E, Snowden J, Mann D, Ertekin-Taner N, Uitti RJ, Wszolek ZK, Josephs KA, Parisi JE, Knopman DS, Petersen RC, Hodges JR, Piguet O, Geier EG, Yokoyama JS, Rissman RA, Rogaeva E, Keith J, Zinman L, Tartaglia MC, Cairns NJ, Cruchaga C, Ghetti B, Kofler J, Lopez OL, Beach TG, Arzberger T, Herms J, Honig LS, Vonsattel JP, Halliday GM, Kwok JB, White CL 3rd, Gearing M, Glass J, Rollinson S, Pickering-Brown S, Rohrer JD, Trojanowski JQ, Van Deerlin V, Bigio EH, Troakes C, Al-Sarraj S, Asmann Y, Miller BL, Graff-Radford NR, Boeve BF, Seeley WW, Mackenzie IRA, van Swieten JC, Dickson DW, Biernacka JM, Rademakers R**
Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD.
Acta Neuropathol. 2019 Jun;137(6):879-899. doi: 10.1007/s00401-019-01962-9. IF 14.251
176. **Preuss U.W, Hoch E, Pogarell O**
Cannabisverschreibung.
Suchtmedizin in Forschung und Praxis 2019; 20(6): 350. IF -
177. **Proebstl L, Kamp F, Hager L, Krause D, Riebschläger M, Neumann S, Schacht Jablonowsky M, Schreiber A, Straif M, Manz K, Soyka M, Koller G**
Associations between methamphetamine use, psychiatric comorbidities and treatment outcome in two inpatient rehabilitation centers.
Psychiatry Res. 2019 Oct;280:112505. doi: 10.1016/j.psychres.2019.112505. IF 2.118
178. **Proebstl L, Kamp F, Manz K, Krause D, Adorjan K, Pogarell O, Koller G, Soyka M, Falkai P, Kambeitz J**
Effects of stimulant drug use on the dopaminergic system: A systematic review and meta-analysis of in vivo neuroimaging studies.
Eur Psychiatry. 2019 Jun;59:15-24. doi: 10.1016/j.eurpsy.2019.03.003. IF 4.464
179. **Proebstl L, Krause D, Kamp F, Hager L, Manz K, Schacht-Jablonowsky M, Straif M, Riebschläger M, Neumann S, Schreiber A, Soyka M, Koller G**
Methamphetamine withdrawal and the restoration of cognitive functions - a study over a course of 6 months abstinence.
Psychiatry Res. 2019 Nov;281:112599. doi: 10.1016/j.psychres.2019.112599. IF 2.118
180. **Prokopenko I, Miyakawa G, Zheng B, Heikkinen J, Petrova Quayle D, Udeh-Momoh C, Claringbould A, Neumann J, Haytural H, Kaakinen MA, Loizidou E, Meissner E, Bertram L; BIOS consortium, Gveric DO, Gentleman SM, Attems J, Perneczky R, Arzberger T, Muglia P, Lill CM, Parkkinen L, Middleton LT**
Alzheimer's disease pathology explains association between dementia with Lewy bodies and APOE-ε4/TOMM40 long poly-T repeat allele variants.
Alzheimers Dement (N Y). 2019 Nov 20;5:814-824. doi: 10.1016/j.trci.2019.08.005. IF 17.127

181. **Quadflieg N, Fichter MM**
Long-term outcome of inpatients with bulimia nervosa-Results from the Christina Barz Study.
Int J Eat Disord. 2019 Jul;52(7):834-845. doi: 10.1002/eat.23084. IF 3.668
182. **Quadflieg N, Strobel C, Naab S, Voderholzer U, Fichter MM**
Mortality in males treated for an eating disorder-A large prospective study.
Int J Eat Disord. 2019 Dec;52(12):1365-1369. doi: 10.1002/eat.23135. IF 3.668
183. **Raabe FJ, Slapakova L, Rossner MJ, Cantuti-Castelvetri L, Simons M, Falkai PG, Schmitt A**
Oligodendrocytes as A New Therapeutic Target in Schizophrenia: From Histopathological Findings to Neuron-Oligodendrocyte Interaction.
Cells. 2019 Nov 23;8(12). pii: E1496. doi: 10.3390/cells8121496. IF 4.366
184. **Rauchmann BS, Schneider-Axmann T, Alexopoulos P, Perneczky R; Alzheimer's Disease Neuroimaging Initiative**
CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.
Neurobiol Aging. 2019 Feb;74:182-190. doi: 10.1016/j.neurobiolaging.2018.10.022. IF 4.347
185. **Rauschmeier R, Gustafsson C, Reinhardt A, A-Gonzalez N, Tortola L, Cansever D, Subramanian S, Taneja R, Rossner MJ, Sieweke MH, Greter M, Månsson R, Busslinger M, Kreslavsky T**
Bhlhe40 and Bhlhe41 transcription factors regulate alveolar macrophage self-renewal and identity.
EMBO J. 2019 Oct 1;38(19):e101233. doi: 10.15252/embj.2018101233. IF 9.889
186. **Reedtz C, van Doesum K, Signorini G, Lauritzen C, van Amelsvoort T, van Santvoort F, Young AH, Conus P, Musil R, Schulze T, Berk M, Stringaris A, Piché G, de Girolamo G**
Promotion of Wellbeing for Children of Parents With Mental Illness: A Model Protocol for Research and Intervention.
Front Psychiatry. 2019 Sep 6;10:606. doi: 10.3389/fpsy.2019.00606. IF 2.849
187. **Reichenberger J, Wiggert N, Wilhelm FH, Liedlgruber M, Voderholzer U, Hillert A, Timmer B, Blechert J**
Fear of negative and positive evaluation and reactivity to social-evaluative videos in social anxiety disorder.
Behav Res Ther. 2019 May;116:140-148. doi: 10.1016/j.brat.2019.03.009. IF 4.500
188. **Reinhard MA, Wilkening A, Müller-Oerlinghausen B, Grohmann R**
Recurring Nephrotic Syndrome after Lithium Medication: A Case Report.
J Clin Psychopharmacol. 2019 Sep/Oct;39(5):516-518. doi: 10.1097/JCP.0000000000001078. IF 2.700
189. **Reker D, Schneider M, Greiner T, Degner D, Toto S, Bleich S, Grohmann R, Heinze M**
Craving unter Mirtazapin. Kasuistik aus dem Projekt "Arzneimittelsicherheit in der Psychiatrie" e.V. (AMSP).
Psychopharmakotherapie 2019; 26: 156-60. IF -

190. **Richard A, Meule A, Georgii C, Voderholzer U, Cuntz U, Wilhelm FH, Blechert J**
Associations between interoceptive sensitivity, intuitive eating, and body mass index in patients with anorexia nervosa and normal-weight controls.
Eur Eat Disord Rev. 2019 Sep;27(5):571-577. doi: 10.1002/erv.2676. IF 3.560
191. **Ridderbusch IC, Richter J, Yang Y, Hoefler M, Weber H, Reif A, Hamm A, Pané-Farré CA, Gerlach AL, Stroehle A, Pfleiderer B, Arolt V, Wittchen HU, Gloster A, Lang T, Helbig-Lang S, Fehm L, Pauli P, Kircher T, Lueken U, Straube B**
Association of rs7688285 allelic variation coding for GLRB with fear reactivity and exposure-based therapy in patients with panic disorder and agoraphobia. Eur Neuropsychopharmacol. 2019 Oct;29(10):1138-1151. doi: 10.1016/j.euroneuro.2019.07.133. IF 6.751
192. **Riso L, Kaaks R, Kühn T, Sookthai D, Forsgren L, Trupp M, Trichopoulou A, La Vecchia C, Karakatsani A, Gavrila D, Ferrari P, Freisling H, Petersson J, Lewan S, Vermeulen RC, Panico S, Masala G, Ardanaz E, Krogh V, Perneczky R, Middleton LT, Mokoroa O, Sacerdote C, Sieri S, Hayat SA, Brayne C, Riboli E, Vineis P, Gallo V, Katzke VA**
General and abdominal adiposity and the risk of Parkinson's disease: A prospective cohort study.
Parkinsonism Relat Disord. 2019 May;62:98-104. doi: 10.1016/j.parkreldis.2019.01.019. IF 3.926
193. **Ristow I, Foell J, Kärgel C, Borchardt V, Li S, Denzel D, Witzel J, Drumkova K, Beier K, Kruger THC, Ponseti J, Schiffer B, Schiltz K, Walter H, Walter M**
Expectation of sexual images of adults and children elicits differential dorsal anterior cingulate cortex activation in pedophilic sexual offenders and healthy controls.
Neuroimage Clin. 2019;23:101863. doi: 10.1016/j.nicl.2019.101863. IF 4.350
194. **Roeh A, Kirchner SK, Malchow B, Maurus I, Schmitt A, Falkai P, Hasan A**
Depression in Somatic Disorders: Is There a Beneficial Effect of Exercise?
Front Psychiatry. 2019 Mar 20;10:141. doi: 10.3389/fpsy.2019.00141. IF 2.849
195. **Roeh A, Schuster T, Jung P, Schneider J, Halle M, Scherr J**
Two dimensional and real-time three dimensional ultrasound measurements of left ventricular diastolic function after marathon running: results from a substudy of the BeMaGIC trial.
Int J Cardiovasc Imaging. 2019 Oct;35(10):1861-1869. doi: 10.1007/s10554-019-01634-5. IF 1.969
196. **Roesmann K, Dellert T, Junghoefer M, Kissler J, Zwitterlood P, Zwanzger P, Dobel C**
The causal role of prefrontal hemispheric asymmetry in valence processing of words - Insights from a combined cTBS-MEG study.
Neuroimage. 2019 May 1;191:367-379. doi: 10.1016/j.neuroimage.2019.01.057. IF 5.902

197. **Roest AM, de Vries YA, Lim CCW, Wittchen HU, Stein DJ, Adamowski T, Al-Hamzawi A, Bromet EJ, Viana MC, de Girolamo G, Demyttenaere K, Florescu S, Gureje O, Haro JM, Hu C, Karam EG, Caldas-de-Almeida JM, Kawakami N, Lépine JP, Levinson D, Medina-Mora ME, Navarro-Mateu F, O'Neill S, Piazza M, Posada-Villa JA, Slade T, Torres Y, Kessler RC, Scott KM, de Jonge P; WHO World Mental Health Survey Collaborators**
A comparison of DSM-5 and DSM-IV agoraphobia in the World Mental Health Surveys.
Depress Anxiety. 2019 Jun;36(6):499-510. doi: 10.1002/da.22885. IF 4.702
198. **Rösner S, Soyka M**
Anti-Craving-Substanzen bei Alkoholabhängigkeit:
Neurologie & Psychiatrie 2019; 27-29. IF -
199. **Rösner S, Soyka M**
Outcome Assessment in Trials of Pharmacological Treatments for Alcohol Use Disorders: Fair and Strict Testing.
CNS Drugs. 2019 Jul;33(7):649-657. doi: 10.1007/s40263-019-00644-0. IF 4.786
200. **Sadlon A, Takousis P, Alexopoulos P, Evangelou E, Prokopenko I, Perneczky R**
miRNAs Identify Shared Pathways in Alzheimer's and Parkinson's Diseases.
Trends Mol Med. 2019 Aug;25(8):662-672. doi: 10.1016/j.molmed.2019.05.006. IF 11.099
201. **Saller T, MacLulich AMJ, Schäfer ST, Crispin A, Neitzert R, Schüle C, von Dossow V, Hofmann-Kiefer KF**
Screening for delirium after surgery: validation of the 4 A's test (4AT) in the post-anaesthesia care unit.
Anaesthesia. 2019 Oct;74(10):1260-1266. doi: 10.1111/anae.14682. IF 5.739
202. **Sanader B, Grohmann R, Grötsch P, Schumann T, Toto S, Fernando P, Stübner S**
Clozapine-Induced DRESS Syndrome: A Case Series From the AMSP Multicenter Drug Safety Surveillance Project.
Pharmacopsychiatry. 2019 Mar;52(3):156-159. doi: 10.1055/a-0586-8983. IF 4.340
203. **Sartorius A, Demirakca T, Böhringer A, Clemm von Hohenberg C, Aksay SS, Bumb JM, Kranaster L, Nickl-Jockschat T, Grözinger M, Thomann PA, Wolf RC, Zwanzger P, Dannlowski U, Redlich R, Zavorotnyy M, Zöllner R, Methfessel I, Besse M, Zilles D, Ende G**
Electroconvulsive Therapy Induced Gray Matter Increase Is Not Necessarily Correlated With Clinical Data in Depressed Patients
Brain Stimul. 2019 Mar - Apr;12(2):335-343. doi: 10.1016/j.brs.2018.11.017. IF 6.565
204. **Sauerbruch T, Benzing Th, Bieber T, Diener H-Ch, Falkai P, Ghadimi BM, Kölbl H, Manger B, Müller SC, Nauck F, Nickenig G, Niebling W-B, Parhofer KG, Rascher W, Schulz R-J, Serve H, Voderholzer U, Vogelmeier C, Weber MM**
Therapie-Handbuch. Jahrbuch 2019. Urban & Fischer, München, 2019.
205. **Schacht-Jablonowsky M, Riebschläger M, Harndorf W, Proebstl L, Kamp F, Koller G, Soyka M**
Spezifika "Crystal"-abhängige Patienten: Vorstellung eines laufenden stationären Forschungsprojektes.
Sucht Aktuell 2019; 102-103. IF -

206. **Schad DJ, Garbusow M, Friedel E, Sommer C, Sebold M, Hägele C, Bernhardt N, Nebe S, Kuitunen-Paul S, Liu S, Eichmann U, Beck A, Wittchen HU, Walter H, Sterzer P, Zimmermann US, Smolka MN, Schlagenhauf F, Huys QJM, Heinz A, Rapp MA**
Neural correlates of instrumental responding in the context of alcohol-related cues index disorder severity and relapse risk.
Eur Arch Psychiatry Clin Neurosci. 2019 Apr;269(3):295-308. doi: 10.1007/s00406-017-0860-4. IF 3.288
207. **Schaub A**
Kognitiv-verhaltenstherapeutische Interventionen bei schizophrenen und verwandten Störungen.
In: Leibing E, Hiller W, Sulz SKD (Hrsg). Lehrbuch der Psychotherapie. Psychosozial Verlag, 2019, S. 231-238.
208. **Schaub A, Falkai P**
Sixth Kraepelin Symposium-Understanding and Treating Cognitive Impairment and Depression in Schizophrenia and Affective Disorders.
Schizophr Bull. 2019 Apr 25;45(3):509-511. doi: 10.1093/schbul/sbz003. IF 7.958
209. **Schennach R, Feige B, Riemann D, Heuser J, Voderholzer U**
Pre- to post-inpatient treatment of subjective sleep quality in 5,481 patients with mental disorders: A longitudinal analysis.
J Sleep Res. 2019 Aug;28(4):e12842. doi: 10.1111/jsr.12842. IF 3.623
210. **Schennach R, Obermeier M, Spellmann I, Seemüller F, Musil R, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Bauer M, Adli M, Zeiler J, Bender W, Kronmüller KT, Ising M, Brieger P, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ, Riedel M**
Remission in schizophrenia - What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression.
Schizophr Res. 2019 Jul;209:185-192. doi: 10.1016/j.schres.2019.04.022. IF 3.759
211. **Schennach R, Riedel M, Spellmann I, Musil R, Obermeier M, Jäger M, Bottlender R, Schmauss M, Laux G, Möller HJ**
Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study.
Pharmacopsychiatry. 2019 Jul;52(4):180-185. doi: 10.1055/a-0669-9461. IF 4.340
212. **Schennach R, Riedel M, Spellmann I, Musil R, Obermeier M, Jäger M, Bottlender R, Schmauss M, Laux G, Möller HJ**
Correction: Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study.
Pharmacopsychiatry. 2019 Jul;52(4):e1. doi: 10.1055/a-1123-8803. IF -
213. **Schiele MA, Kollert L, Lesch KP, Arolt V, Zwanzger P, Deckert J, Ziegler C, Domschke K**
Hypermethylation of the serotonin transporter gene promoter in panic disorder- Epigenetic imprint of comorbid depression?
Eur Neuropsychopharmacol. 2019 Oct;29(10):1161-1167. doi: 10.1016/j.euroneuro.2019.07.131. IF 3.853

214. **Schlegl S, Hupe K, Hessler JB, Diedrich A, Huber T, Rauh E, Aita S, Gärtner T, Voderholzer U**
[Pathways to Care and Duration of Untreated Illness of Inpatients with Anorexia and Bulimia nervosa].
Psychiatr Prax. 2019 Sep;46(6):342-348. doi: 10.1055/a-0922-5651. IF 1.723
215. **Schmelz M, Häuser W, Hoch E, Petzke F, Sommer C**
Cannabisbasierte Arzneimittel. Expertenkonsens gegen systematische Übersichtsarbeiten.
Schmerz. 2019 Apr;33(2):97-99. doi: 10.1007/s00482-018-0349-8. IF 0.964
216. **Schmidt SJ, Hurlemann R, Schultz J, Wasserthal S, Kloss C, Maier W, Meyer-Lindenberg A, Hellmich M, Muthesius-Digón A, Pantel T, Wiesner PS, Klosterkötter J, Ruhrmann S; ESPRIT-B1 Group**
Multimodal prevention of first psychotic episode through N-acetyl-L-cysteine and integrated preventive psychological intervention in individuals clinically at high risk for psychosis: Protocol of a randomized, placebo-controlled, parallel-group trial.
Early Interv Psychiatry. 2019 Dec;13(6):1404-1415. doi: 10.1111/eip.12781. IF 2.257
217. **Schmitt A, Reich-Erkelenz D, Hasan A, Falkai P**
Aerobic exercise in mental disorders: from basic mechanisms to treatment recommendations.
Eur Arch Psychiatry Clin Neurosci. 2019 Aug;269(5):483-484. doi: 10.1007/s00406-019-01037-6. IF 3.288
218. **Schmitt A, Simons M, Cantuti-Castelvetri L, Falkai P**
A new role for oligodendrocytes and myelination in schizophrenia and affective disorders?
Eur Arch Psychiatry Clin Neurosci. 2019 Jun;269(4):371-372. doi: 10.1007/s00406-019-01019-8. IF 3.288
219. **Schneider M, Greiner T, Degner D, Bleich S, Grohmann R, Toto S, Heinze M**
Harnverhalten unter der Kombinationstherapie aus Mirtazapin, Risperidon und Solifenacin.
Kasuistik aus dem Projekt "Arzneimittelsicherheit in der Psychiatrie" e.V. (AMSP).
Psychopharmakotherapie 2019; 26: 299-302. IF -
220. **Schnell JML, Weidinger E, Musil R**
[Patients with tic disorders: widely known, yet underserved].
Fortschr Neurol Psychiatr. 2019 Oct;87(10):577-589. doi: 10.1055/a-0996-0944. IF 0.642
221. **Schöne M, Seidenbecher S, Tozzi L, Kaufmann J, Griep H, Fenker D, Frodl T, Bogerts B, Schiltz K**
Neurobiological correlates of violence perception in martial artists.
Brain Behav. 2019 May;9(5):e01276. doi: 10.1002/brb3.1276. IF 2.091

222. **Schrag A, Martino D, Apter A, Ball J, Bartolini E, Benaroya-Milshtein N, Buttiglione M, Cardona F, Creti R, Efstratiou A, Gariup M, Georgitsi M, Hedderly T, Heyman I, Margarit I, Mir P, Moll N, Morer A, Müller N, Müller-Vahl K, Münchau A, Orefici G, Plessen KJ, Porcelli C, Paschou P, Rizzo R, Roessner V, Schwarz MJ, Steinberg T, Tagwerker Gloor F, Tarnok Z, Walitza S, Dietrich A, Hoekstra PJ; EMTICS Collaborative Group**
European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents.
Eur Child Adolesc Psychiatry. 2019 Jan;28(1):91-109. doi: 10.1007/s00787-018-1190-4. IF 3.941
223. **Schulz J, Takousis P, Wohlers I, Itua IOG, Dobricic V, Rücker G, Binder H, Middleton L, Ioannidis JPA, Perneczky R, Bertram L, Lill CM**
Meta-analyses identify differentially expressed micrnas in Parkinson's disease.
Ann Neurol. 2019 Jun;85(6):835-851. doi: 10.1002/ana.25490. IF 9.037
224. **Schumann C, Alexopoulos P, Perneczky R**
Determinants of self- and carer-rated quality of life and caregiver burden in Alzheimer disease.
Int J Geriatr Psychiatry. 2019 Oct;34(10):1378-1385. doi: 10.1002/gps.5126. IF 2.675
225. **Schwartz C, Drexl K, Fischer A, Fumi M, Löwe B, Naab S, Voderholzer U**
Universal prevention in eating disorders: a systematic narrative review of recent studies.
Mental Health & Prevention 2019; 14: 200162. IF –
226. **Schwarzmeier H, Kleint NI, Wittchen HU, Ströhle A, Hamm AO, Lueken U**
Characterizing the nature of emotional-associative learning deficits in panic disorder: An fMRI study on fear conditioning, extinction training and recall.
Eur Neuropsychopharmacol. 2019 Dec;29(2):306-318. doi: 0.1016/j.euroneuro.2018.11.1108. IF 3.853
227. **Scott J, Hidalgo-Mazzei D, Strawbridge R, Young A, Resche-Rigon M, Etain B, Andreassen OA, Bauer M, Bennabi D, Blamire AM, Boumezbeur F, Brambilla P, Cattane N, Cattaneo A, Chupin M, Coello K, Cointepas Y, Colom F, Cousins DA, Dubertret C, Duchesnay E, Ferro A, Garcia-Estela A, Goikolea J, Grigis A, Haffen E, Høegh MC, Jakobsen P, Kalman JL, Kessing LV, Klohn-Saghatolislam F, Lagerberg TV, Landén M, Lewitzka U, Lutticke A, Mazer N, Mazzelli M, Mora C, Muller T, Mur-Mila E, Oedegaard KJ, Olstedal L, Pålsson E, Papadopoulos Orfanos D, Papiol S, Perez-Sola V, Reif A, Ritter P, Rossi R, Schulze T, Senner F, Smith FE, Squarcina L, Steen NE, Thelwall PE, Varo C, Vieta E, Vinberg M, Wessa M, Westlye LT, Bellivier F**
Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative.
Int J Bipolar Disord. 2019 Sep 25;7(1):20. doi: 10.1186/s40345-019-0156-x. IF 2.966
228. **Seeger F, Yang Y, Straube B, Kircher T, Höfler M, Wittchen HU, Ströhle A, Wittmann A, Gerlach AL, Pfeleiderer B, Arolt V, Hamm A, Lang T, Alpers GW, Fydrich T, Lueken U**
Clinical and Neurofunctional Substrates of Cognitive Behavioral Therapy on Secondary Social Anxiety Disorder in Primary Panic Disorder: A Longitudinal fMRI Study.
Psychother Psychosom. 2019;88(1):48-51. doi: 10.1159/000493756. IF 14.864

- 229. Sekutowicz M, Guggenmos M, Kuitunen-Paul S, Garbusow M, Sebold M, Pelz P, Priller J, Wittchen HU, Smolka MN, Zimmermann US, Heinz A, Sterzer P, Schmack K**
Neural Response Patterns During Pavlovian-to-Instrumental Transfer Predict Alcohol Relapse and Young Adult Drinking.
Biol Psychiatry 2019; 86(11): 857-863. doi: 10.1016/j.biopsych.2019.06.028. IF 12.095
- 230. Shang J, Fisher P, Bäuml JG, Daamen M, Baumann N, Zimmer C, Bartmann P, Boecker H, Wolke D, Sorg C, Koutsouleris N, Dwyer DB**
A machine learning investigation of volumetric and functional MRI abnormalities in adults born preterm.
Hum Brain Mapp 2019; 40: 4239-4252. doi: 10.1002/hbm.24698. IF 4.421
- 231. Siskind D, Honarparvar F, Hasan A, Wagner E, Sinha S, Orr S, Kisely S**
rTMS for clozapine refractory schizophrenia - A systematic review and pairwise meta-analysis.
Schizophr Res. 2019; 211: 113-114. doi: 10.1016/j.schres.2019.07.004. IF 3.759
- 232. Sommer IEC, Oomen PP, Hasan A**
Maintenance treatment for patients with a first psychotic episode.
Curr Opin Psychiatry 2019; 32(3): 147-156. doi: 10.1097/YCO.0000000000000494. IF 4.392
- 233. Soyka M**
Affektive und Angststörungen und komorbide Suchterkrankungen.
In: Walter, W, Gouzoulis-Mayfrank E (Hrsg).
Psychische Störungen und Suchterkrankungen. Diagnostik und Behandlung von Doppeldiagnosen.
Kohlhammer, Stuttgart, 2019, S. 118-136.
- 234. Soyka M**
Diagnostische Kriterien für Suchterkrankungen.
In: Soyka M, Batra A, Heinz A, Moggi F, Walter M (Hrsg.)
Suchtmedizin.
Elsevier, München, 2019, S. 3-11.
- 235. Soyka M**
Notfallsituationen.
In: Soyka M, Batra A, Heinz A, Moggi F, Walter M (Hrsg.)
Suchtmedizin.
Elsevier, München, 2019, S. 319-332.
- 236. Soyka M**
Sollen Glückspielsüchtige Rechtsbrecher zukünftig im Maßregelvollzug behandelt werden?
Suchtmed 2019; 21: 41-44. IF -
- 237. Soyka M**
[Treatment of Benzodiazepine Dependence]
Therapie der Benzodiazepinabhängigkeit.
Fortschr Neurol Psychiatr 2019; 87: 259-270. doi: 10.1055/a-0836-7514. IF 0.642

- 238. Soyka M, Batra A**
Benzodiazepinabhängigkeit (ICD-10 F 13.2)
In: Voderholzer U, Hohagen F (Hrsg).
Therapie psychischer Erkrankungen. State of the Art.
Elsevier, Urban & Fischer, München, 2019, S. 71-79.
- 239. Soyka M, Batra A, Heinz A, Moggi F, Walter M**
Suchtmedizin. Elsevier, München, 2018.
- 240. Soyka M, Baumgärtner G**
Psychotherapeutische Interventionen bei Abhängigkeitserkrankten.
In: Führer E, Funke W, Lippe M, Stöpel J
Abstinenz-Sicherungs-Training (A-S-Train) für Menschen ohne Job.
Lambertus, 2019, S. 202-213
- 241. Soyka M, Franke A**
Medikamentenabhängigkeit und komorbide psychische Störungen.
In: Walter, W, Gouzoulis-Mayfrank E (Hrsg).
Psychische Störungen und Suchterkrankungen. Diagnostik und Behandlung von
Doppeldiagnosen.
Kohlhammer, Stuttgart, 2019, S. 244-255.
- 242. Soyka M, Mutschler J, Rösner S**
Pharmakotherapie der Alkoholabhängigkeit. Craving mildern.
DNP Der Neurologe & Psychiater 2019; 20: 42-47. IF -
- 243. Soyka M, Pogarell O**
[New Slow-Release Buprenorphine Formulations for Optimization of Opioid
Substitution].
Neue Slow-release-Buprenorphinformulierungen zur Optimierung der
Opioids substitution.
Nervenarzt 2019; 90: 932-937. doi: 10.1007/s00115-019-0783-6. IF 0.824
- 244. Stegmann Y, Schiele MA, Schümann D, Lonsdorf TB, Zwanzger P, Romanos M,
Reif A, Domschke K, Deckert J, Gamer M, Pauli P**
Individual differences in human fear generalization-pattern identification and
implications for anxiety disorders.
Transl Psychiatry. 2019; 9(1): 307. doi: 10.1038/s41398-019-0646-8. IF 5.280
- 245. Steiner J, Fernandes BS, Guest PC, Dobrowolny H, Meyer-Lotz G, Westphal S,
Borucki K, Schiltz K, Sarnyai Z, Bernstein HG**
Glucose homeostasis in major depression and schizophrenia: a comparison among
drug-naïve first-episode patients.
Eur Arch Psychiatry Clin Neurosci 2019; 269: 373-377. doi: 10.1007/s00406-018-
0865-7. IF 3.288
- 246. Stephan M, Volkmann P, Rossner MJ**
Assessing behavior and cognition in rodents, nonhuman primates, and humans:
where are the limits of translation?
Dialogues Clin Neurosci 2019; 21(3): 249-259. doi:
10.31887/DCNS.2019.21.3/mrossner. IF 5.397

247. **Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, Brueckner S, Brosch M, Heimes CV, Woditsch V, Scholten D, Nischalke HD, Janciauskiene S, Mandorfer M, Trauner M, Way MJ, McQuillin A, Reichert MC, Krawczyk M, Casper M, Lammert F, Braun F, von Schönfels W, Hinz S, Burmeister G, Hellerbrand C, Teufel A, Feldman A, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T², Ridinger M, Wodarz N, Soyka M, Rietschel M, Kiefer F, Weber T, Marhenke S, Vogel A, Hinrichsen H, Canbay A, Schlattjan M, Sosnowsky K, Sarrazin C, von Felden J, Geier A, Deltenre P, Sipos B, Schafmayer C, Nothnagel M, Aigner E, Datz C, Stickel F, Morgan MY, Hampe J, Berg T, Trautwein C**
Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. doi: 10.1136/gutjnl-2018-316228.
Gut 2019; 68: 1099-1107. IF 19.819
248. **Strobel C, Quadflieg N, Naab S, Voderholzer U, Fichter MM**
Long-term outcomes in treated males with anorexia nervosa and bulimia nervosa-A prospective, gender-matched study.
Int J Eat Disord 2019; 52(12): 1353-1364. doi: 10.1002/eat.23151. IF 3.668
249. **Swarup V, Hinz FI, Rexach JE, Noguchi KI, Toyoshiba H, Oda A, Hirai K, Sarkar A, Seyfried NT, Cheng C, Haggarty SJ; International Frontotemporal Dementia Genomics Consortium, Grossman M, Van Deerlin VM, Trojanowski JQ, Lah JJ, Levey AI, Kondou S, Geschwind DH**
Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia.
Nat Med 2019; 25: 152-164. doi: 10.1038/s41591-018-0223-3. IF 36.130
250. **Takousis P, Sadlon A, Schulz J, Wohlers I, Dobricic V, Middleton L, Lill CM, Perneczky R, Bertram L**
Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid.
Alzheimers Dement 2019; 15: 1468-1477. doi: 10.1016/j.jalz.2019.06.4952.
IF 17.127
251. **Thibaut F, Chagraoui A, Buckley L, Gressier F, Labad J, Lamy S, Potenza MN, Rondon M, Riecher-Rössler A, Soyka M, Yonkers K**
WFSBP * and IAWMH ** Guidelines for the treatment of alcohol use disorders in pregnant women.
World J Biol Psychiatry 2019; 20: 17-50. doi: 10.1080/15622975.2018.1510185.
IF 4.164
252. **Tomasik J, Lago SG, Vázquez-Bourgon J, Papiol S, Suárez-Pinilla P, Crespo-Facorro B, Bahn S**
Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic Treatment.
JAMA Psychiatry 2019; 76: 864-867. doi: 10.1001/jamapsychiatry.2019.0304.
IF 17.471
253. **Toto S, Grohmann R, Bleich S, Frieling H, Maier HB, Greil W, Cordes J, Schmidt-Kraepelin C, Kasper S, Stübner S, Degner D, Druschky K, Zindler T, Neyazi A**
Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study.
Int J Neuropsychopharmacol 2019; 22: 560-573. doi: 10.1093/ijnp/pyz037. IF 4.333

254. **Trautmann S, Richter J, Muehlhan M, Höfler M, Wittchen HU, Domschke K, Ströhle A, Hamm AO, Weber H, Kircher T, Arolt V, Gerlach AL, Alpers GW, Fydrich T, Lang T, Reif A**
Does prior traumatization affect the treatment outcome of CBT for panic disorder? The potential role of the MAOA gene and depression symptoms.
Eur Arch Psychiatry Clin Neurosci 2019; 269(2): 161-170. doi: 10.1007/s00406-017-0823-9. IF 3.288
255. **Trossbach SV, Hecher L, Schafflick D, Deenen R, Popa O, Lautwein T, Tschirner S, Köhrer K, Fehsel K, Papazova I, Malchow B, Hasan A, Winterer G, Schmitt A, Meyer Zu Hörste G, Falkai P, Korth C**
Dysregulation of a specific immune-related network of genes biologically defines a subset of schizophrenia.
Transl Psychiatry 2019; 9(1): 156. doi: 10.1038/s41398-019-0486-6. IF 5.280
256. **Udeh-Momoh C, Price G, Ropacki MT, Ketter N, Andrews T, Arrighi HM, Brashear HR, Robb C, Bassil DT, Cohn M, Curry LK, Su B, Perera D, Giannakopoulou P, Car J, Ward HA, Perneczky R, Novak G, Middleton L**
Prospective Evaluation of Cognitive Health and Related Factors in Elderly at Risk for Developing Alzheimer's Dementia: A Longitudinal Cohort Study.
J Prev Alzheimers Dis 2019; 6: 256-266. doi: 10.14283/jpad.2019.31. IF 3.149
257. **Udeh-Momoh CT, Su B, Evans S, Zheng B, Sindi S, Tzoulaki I, Perneczky R, Middleton LT; Alzheimer's Disease Neuroimaging Initiative**
Cortisol, Amyloid- β , and Reserve Predicts Alzheimer's Disease Progression for Cognitively Normal Older Adults.
J Alzheimers Dis 2019; 70: 553-562. doi: 10.3233/JAD-181030. IF 3.909
258. **Van Tebartz Elst L, Bechter K, Prüss H, Hasan A, Steiner JH, Leyboldt F, Endres D**
[Autoantibody-associated schizophreniform psychoses: pathophysiology, diagnostics, and treatment].
Nervenarzt 2019; 90(7): 745-761. doi: 10.1007/s00115-019-0735-1. IF 0.824
259. **van Well EM, Bader V, Patra M, Sánchez-Vicente A, Meschede J, Furthmann N, Schnack C, Blusch A, Longworth J, Petrasch-Parwez E, Mori K, Arzberger T, Trümbach D, Angersbach L, Showkat C, Sehr DA, Berlemann LA, Goldmann P, Clement AM, Behl C, Woerner AC, Saft C, Wurst W, Haass C, Ellrichmann G, Gold R, Dittmar G, Hipp MS, Hartl FU, Tatzelt J, Winklhofer KF**
A protein quality control pathway regulated by linear ubiquitination.
EMBO J 2019; 38(9). e100730. doi: 10.15252/embj.2018100730. IF 9.889
260. **Velásquez E, Martins-de-Souza D, Velásquez I, Carneiro GRA, Schmitt A, Falkai P, Domont GB, Nogueira FCS**
Quantitative Subcellular Proteomics of the Orbitofrontal Cortex of Schizophrenia Patients.
J Proteome Res 2019; 18(12): 4240-4253. doi: 10.1021/acs.jproteome.9b00398. IF 4.074
261. **Veselinović T, Scharpenberg M, Heinze M, Cordes J, Mühlbauer B, Juckel G, Habel U, Rüter E, Timm J, Gründer G; NeSSy Study Group**
Disparate effects of first and second generation antipsychotics on cognition in schizophrenia - Findings from the randomized NeSSy trial
Eur Neuropsychopharmacol. 2019 Jun;29(6):720-739. doi: 10.1016/j.euroneuro.2019.03.014. IF 3.853

- 262. Voderholzer U, Barton B**
Psychotherapieverfahren und Methoden.
In: Voderholzer U, Hohagen F (Hrsg).
Therapie psychischer Erkrankungen. State of the Art.
Elsevier, Urban & Fischer, München, 2019, S. 541-551.
- 263. Voderholzer U, Barton B**
Sexueller Missbrauch.
In: Voderholzer U, Hohagen F (Hrsg).
Therapie psychischer Erkrankungen. State of the Art.
Elsevier, Urban & Fischer, München, 2019, S. 579-587.
- 264. Voderholzer U, Frauenknecht S**
Essstörungen.
In: Lieb K, Frauenknecht S
Intensivkurs Psychiatrie und Psychotherapie. Elsevier, 2019, S. 299-317.
- 265. Voderholzer U, Frauenknecht S**
Schlafstörungen.
In: Lieb K, Frauenknecht S
Intensivkurs Psychiatrie und Psychotherapie. Elsevier, 2019, S. 421-438.
- 266. Voderholzer U, Hessler JB, Naab S, Fichter M, Graetz A, Greetfeld M, Heuser J, Schlegl S**
Are there differences between men and women in outcome of intensive inpatient treatment for anorexia nervosa? An analysis of routine data.
Eur Eat Disord Rev 2019; 27(1): 59-66. doi: 10.1002/erv.2624. IF 3.560
- 267. Voderholzer U, Hohagen F**
Therapie psychischer Erkrankungen.
Elsevier, Urban & Fischer, München, 2019.
- 268. Voderholzer U, Külz AK**
Zwangsstörungen.
In: Sauerbruch T, Benzing Th, Bieber T, Diener H-Ch, Falkai P, Ghadimi BM, Kölbl H, Manger B, Müller SC, Nauck F, Nickenig G, Niebling W-B, Parhofer KG, Rascher W, Schulz R-J, Serve H, Voderholzer U, Vogelmeier C, Weber MM
Therapie-Handbuch. Jahrbuch 2019. Urban & Fischer, München, 2019, S. 549-544.
- 269. Vogel D, Falter-Wagner CM, Schoofs T, Krämer K, Kupke C, Vogeley K**
Interrupted Time Experience in Autism Spectrum Disorder: Empirical Evidence from Content Analysis.
J Autism Dev Disord. 2019; 49(1): 22-33. doi: 10.1007/s10803-018-3771-y. IF 3.047
- 270. von Siemens SM, Perneczky R, Vogelmeier CF, Behr J, Kauffmann-Guerrero D, Alter P, Trudzinski FC, Bals R, Grohé C, Söhler S, Waschki B, Lutter JI, Welte T, Jörres RA, Kahnert K; COSYCONET study group**
The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort.
Respir Res 2019; 20: 257. doi: 10.1186/s12931-019-1217-5. IF 3.924

271. **Wagner E, Löhrs L, Siskind D, Honer WG, Falkai P, Hasan A**
Clozapine augmentation strategies - a systematic meta-review of available evidence.
Treatment options for clozapine resistance.
J Psychopharmacol 2019; 33(4): 423-435. doi: 10.1177/0269881118822171. IF 3.121
272. **Wagner E, Wobrock T, Kunze B, Langguth B, Landgrebe M, Eichhammer P, Frank E, Cordes J, Wölwer W, Winterer G, Gaebel W, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Siskind D, Malchow B, Strube W, Schneider-Axmann T, Falkai P, Hasan A**
Efficacy of high-frequency repetitive transcranial magnetic stimulation in schizophrenia patients with treatment-resistant negative symptoms treated with clozapine.
Schizophr Res 2019; 208: 370-376. doi: 10.1016/j.schres.2019.01.021. IF 3.759
273. **Walter M, Alizadeh S, Jamalabadi H, Lueken U, Dannlowski U, Walter H, Olbrich S, Colic L, Kambeitz J, Koutsouleris N, Hahn T, Dwyer DB**
Translational machine learning for psychiatric neuroimaging.
Prog Neuropsychopharmacol Biol Psychiatry 2019; 91: 113-121. doi: 10.1016/j.pnpbp.2018.09.014. IF 4.361
274. **Walter M, Soyka M**
Opioide.
In: Soyka M, Batra A, Heinz A, Moggi F, Walter M (Hrsg.)
Suchtmedizin.
Elsevier, München, 2019, S. 177-201.
275. **Watson HJ, Yilmaz Z, Thornton LM, Hübel C, Coleman JRI, Gaspar HA, Bryois J, Hinney A, Leppä VM, Mattheisen M, Medland SE, Ripke S, Yao S, Giusti-Rodríguez P; Anorexia Nervosa Genetics Initiative, Hanscombe KB, Purves KL; Eating Disorders Working Group of the Psychiatric Genomics Consortium, Adan RAH, Alfredsson L, Ando T, Andreassen OA, Baker JH, Berrettini WH, Boehm I, Boni C, Perica VB, Buehren K, Burghardt R, Cassina M, Cichon S, Clementi M, Cone RD, Courtet P, Crow S, Crowley JJ, Danner UN, Davis OSP, de Zwaan M, Dedoussis G, Degortes D, DeSocio JE, Dick DM, Dikeos D, Dina C, Dmitrzak-Weglarz M, Docampo E, Duncan LE, Egberts K, Ehrlich S, Escaramís G, Esko T, Estivill X, Farmer A, Favaro A, Fernández-Aranda F, Fichter MM, Fischer K, Föcker M, Foretova L, Forstner AJ, Forzan M, Franklin CS, Gallinger S, Giegling I, Giuranna J, Gonidakis F, Gorwood P, Mayora MG, Guillaume S, Guo Y, Hakonarson H, Hatzikotoulas K, Hauser J, Hebebrand J, Helder SG, Herms S, Herpertz-Dahlmann B, Herzog W, Huckins LM, Hudson JI, Imgart H, Inoko H, Janout V, Jiménez-Murcia S, Julià A, Kalsi G, Kaminská D, Kaprio J, Karhunen L, Karwautz A, Kas MJH, Kennedy JL, Keski-Rahkonen A, Kiezebrink K, Kim YR, Klareskog L, Klump KL, Knudsen GPS, La Via MC, Le Hellard S, Levitan RD, Li D, Lilienfeld L, Lin BD, Lissowska J, Luykx J, Magistretti PJ, Maj M, Mannik K, Marsal S, Marshall CR, Mattingsdal M, McDewitt S, McGuffin P, Metspalu A, Meulenbelt I, Micali N, Mitchell K, Monteleone AM, Monteleone P, Munn-Chernoff MA, Nacmias B, Navratilova M, Ntalla I, O'Toole JK, Ophoff RA, Padyukov L, Palotie A, Pantel J, Papezova H, Pinto D, Rabionet R, Raevuori A, Ramoz N, Reichborn-Kjennerud T, Ricca V, Ripatti S, Ritschel F, Roberts M, Rotondo A, Rujescu D, Rybakowski F, Santonastaso P, Scherag A, Scherer SW, Schmidt U, Schork NJ, Schosser A, Seitz J, Slachтова L, Slagboom PE, Slof-Op 't Landt MCT, Slopian A, Sorbi S, Świątkowska B, Szatkiewicz JP, Tachmazidou I, Tenconi E, Tortorella A, Tozzi F, Treasure J, Tsitsika A, Tyszkiewicz-Nwafor M, Tziouvas K, van Elburg AA, van Furth EF, Wagner G, Walton E, Widen E, Zeggini E, Zerwas S, Zipfel S, Bergen AW, Boden JM, Brandt H, Crawford S, Halmi KA, Horwood LJ, Johnson C, Kaplan AS, Kaye WH, Mitchell JE, Olsen CM, Pearson**

JF, Pedersen NL, Strober M, Werge T, Whiteman DC, Woodside DB, Stuber GD, Gordon S, Grove J, Henders AK, Jureus A, Kirk KM, Larsen JT, Parker R, Petersen L, Jordan J, Kennedy M, Montgomery GW, Wade TD, Birgegård A, Lichtenstein P, Norring C, Landén M, Martin NG, Mortensen PB, Sullivan PF, Breen G, Bulik CM

Genome-wide association study identifies eight risk loci and implicates metabolic-psychiatric origins for anorexia nervosa.

Nat Genet 2019; 51(8): 1207-1214. doi: 10.1038/s41588-019-0439-2. IF 27.603

276. **Wessels H, Wagner M, Kuhr K, Berning J, Pützfeld V, Janssen B, Bottlender R, Maurer K, Möller HJ, Gaebel W, Häfner H, Maier W, Klosterkötter J, Bechdolf A**
Predictors of treatment response to psychological interventions in people at clinical high risk of first-episode psychosis.

Early Interv Psychiatry 2019; 13: 120-127. doi: 10.1111/eip.12460. IF 2.257

277. **Wiechers M, Übleis A, Padberg F**

Empowerment für Menschen mit affektiven Erkrankungen und Migrationserfahrungen.

Schattauer, Stuttgart, 2019.

278. **Wilkening A, Kurzeck A, Dechantsreiter E, Padberg F, Palm U**

Transcranial alternating current stimulation for the treatment of major depression during pregnancy.

Psychiatry Res 2019; 279: 399-400. doi: 10.1016/j.psychres.2019.06.009. IF 2.118

279. **Wilkening A, Palm U**

[Increased Clozapine Levels During Infection: more Frequent than Assumed?]

Psychiatr Prax 2019; 46: 287-289. doi: 10.1055/a-0884-3980. IF 1.723

280. **Wintgens JP, Wichert SP, Popovic L, Rossner MJ, Wehr MC**

Monitoring activities of receptor tyrosine kinases using a universal adapter in genetically encoded split TEV assays.

Cell Mol Life Sci 2019; 76(6): 1185-1199. doi: 10.1007/s00018-018-03003-2. IF 6.496

281. **Wintgens JP, Wichert SP, Popovic L, Rossner MJ, Wehr MC**

Correction to: Monitoring activities of receptor tyrosine kinases using a universal adapter in genetically encoded split TEV assays.

Cell Mol Life Sci 2019; 76(19): 3915. doi: 10.1007/s00018-019-03244-9. IF -

282. **Wittekind CE, Reibert E, Takano K, Ehring T, Pogarell O, Rüther T**

Approach-avoidance modification as an add-on in smoking cessation: A randomized-controlled study.

Behav Res Ther 2019; 114: 35-43. doi: 10.1016/j.brat.2018.12.004. IF 4.500

283. **Wodarz N, Wolstein J, Wodarz-von Essen H, Pogarell O**

Naloxon - Medical basics and international experience.

Sucht – Zeitschrift für Wissenschaft und Praxis 2019; 65: 335-342. IF -

284. **Wojtala J, Heber IA, Neuser P, Heller J, Kalbe E, Rehberg SP, Storch A, Linse K, Schneider C, Gräber S, Berg D, Dams J, Balzer-Geldsetzer M, Hilker-Roggendorf R, Oberschmidt C, Baudrexel S, Witt K, Schmidt N, Deuschl G, Mollenhauer B, Trenkwalder C, Liepelt-Scarfone I, Spottke A, Roeske S, Wüllner U, Wittchen HU, Riedel O, Dodel R, Schulz JB, Reetz K**
Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition.
J Neurol Neurosurg Psychiatry 2019; 90: 171-179. doi: 10.1136/jnnp-2018-319008. IF 8.234
285. **Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, Nietzsche S, Westermann M, Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, Megens RTA, Steffens S, Hildner M, Halder LD, Eckstein HH, Pelisek J, Herms J, Roeber S, Arzberger T, Borodovsky A, Habenicht L, Binder CJ, Weber C, Zipfel PF, Skerka C, Habenicht AJR**
ApoE attenuates unresolvable inflammation by complex formation with activated C1q.
Nat Med 2019; 25(3): 496-506. doi: 10.1038/s41591-018-0336-8. IF 36.130
286. **Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, Nietzsche S, Westermann M, Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, Megens RTA, Steffens S, Hildner M, Halder LD, Eckstein HH, Pelisek J, Herms J, Roeber S, Arzberger T, Borodovsky A, Habenicht L, Binder CJ, Weber C, Zipfel PF, Skerka C, Habenicht AJR**
Publisher Correction: ApoE attenuates unresolvable inflammation by complex formation with activated C1q.
Nat Med 2019; 25: 529. doi: 10.1038/s41591-019-0378-6. IF -
287. **Yitayih Y, Soboka M, Tesfaye E, Abera M, Mamaru A, Adorjan K**
Trauma exposure and alcohol use disorder among prisoners in Jimma Zone correctional institution, Southwest Ethiopia: a cross-sectional study.
BMC Res Notes 2019; 12: 748. doi: 10.1186/s13104-019-4796-9. IF -
288. **Zäske H, Linden M, Degner D, Jockers-Scherübl M, Klingberg S, Klosterkötter J, Maier W, Möller HJ, Sauer H, Schmitt A, Gaebel W**
Stigma experiences and perceived stigma in patients with first-episode schizophrenia in the course of 1 year after their first in-patient treatment.
Eur Arch Psychiatry Clin Neurosci 2019; 269(4): 459-468. doi: 10.1007/s00406-018-0892-4. IF 3.288
289. **Zimmermann GS, Rütger T, Ziegler FV, Greif M, Becker C, Becker A**
Predictive value of coronary calcifications for future cardiac events in asymptomatic patients: underestimation of risk in asymptomatic smokers.
Int J Cardiovasc Imaging 2019; 35(7): 1387-1393. doi: 10.1007/s10554-019-01571-3. IF 1.969